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ABSTRACT 
Among heat shock proteins, Hsp90 is unusual because it is not required for the 
proper folding of most cellular proteins but rather is disproportionally linked to the 
activation of signal transduction proteins including over forty kinases and many steroid 
hormone receptors.  Mutated forms of many Hsp90 clients are causative agents in cancer, 
making Hsp90 a promising pharmacological target. Many small molecular inhibitors 
have been identified that competitively bind to the ATP binding site of Hsp90, some of 
which are in clinical trials as anticancer agents.  Although the activation of kinase and 
hormone receptor clients by Hsp90 and its co-chaperones has been extensively studied, 
the molecular mechanism of client protein activation is poorly understood.  
 
Hsp90 is a dimeric chaperone containing three domains: the N-terminal (N) and 
middle (M) domains contribute directly to ATP binding and hydrolysis and the C-
terminal (C) domain mediates dimerization. At physiological concentration, Hsp90 
predominantly forms dimers, but the possibility that full-length monomers might also 
function in cells has not been tested. In Chapter 3, we used a single-chain strategy to 
design a full-length Hsp90 monomer (NMCC). The resulting construct was 
predominantly monomeric at physiological concentration and did not function to support 
yeast viability as the sole Hsp90. NMCC Hsp90 was also defective at ATP hydrolysis 
and the activation of kinase and steroid hormone receptor clients in yeast cells. The 
ability to support yeast growth was rescued by the addition of a coiled-coil dimerization 
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domain, indicating that the parental single-chain construct is functionally defective 
because it is monomeric.  
 
After finding that a full-length Hsp90 monomer containing only one ATPase site 
was unable to support yeast viability or activate Hsp90 clients, we set out to further 
explore the role of ATPase activity in client protein activation. Approximately 10 % of 
the yeast proteome binds to Hsp90 making it important to study Hsp90 function in the 
cellular environment where all binding partners are present. In Chapter 4, we observed 
that co-expression of different Hsp90 subunits in Saccharomyces cerevisiae caused 
unpredictable synthetic growth defects due to cross-dimerization. We engineered super-
stabilized Hsp90 dimers that resisted cross-dimerization with endogenous Hsp90 and 
alleviated the synthetic growth defect. We utilized these super-stabilized dimers to 
analyze the ability of ATPase mutant homodimers to activate known Hsp90 client 
proteins in yeast cells. We found that ATP binding and hydrolysis by Hsp90 are both 
required for the efficient maturation of the glucocorticoid hormone receptor (GR) and v-
src confirming the critical role of ATP hydrolysis in the maturation of steroid hormone 
receptors and kinases in vivo.  
 
In addition to its role in the activation of signal transduction client proteins, 
Hsp90 has been shown to suppress the in vitro aggregation of numerous hard-to-fold 
proteins. In Chapter 5, we examine the role of charge in Hsp90 anti-aggregation activity. 
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The charge on Hsp90 is largely concentrated in two highly acidic regions. We found that 
deletion of both charge-rich regions dramatically impaired Hsp90 anti-aggregation 
activity. Addition of an acid-rich region with a distinct amino acid sequence to our 
double-deleted Hsp90 construct rescued the anti-aggregation activity of Hsp90 indicating 
that the net charge contributes to its anti-aggregation activity. 
 
The in vitro anti-aggregation activity of Hsp90 studied in Chapter 5 occurs in the 
absence of ATP. However, all of the biologically important functions of Hsp90 in cells 
identified to date, including the maturation of kinases and nuclear steroid hormone 
receptors, clearly require ATP hydrolysis. Why does Hsp90 robustly hinder the 
aggregation of hard-to-fold proteins without ATP in vitro, but in vivo uses ATP 
hydrolysis for all of its essential functions? By utilizing separation of function Hsp90 
variants (that specifically lack in vitro anti-aggregation activity) we have begun to 
address this question. We find that anti-aggregation deficient Hsp90 is unable to support 
yeast growth under stressful conditions, potentially due to reduced cellular expression. 
Interestingly, the ATP-independent anti-aggregation activity of Hsp90 has no 
measureable impact on cellular function. Thus, hindering the aggregation of most hard-
to-fold proteins by Hsp90 (independent of ATP hydrolysis) does not appear to be 
important for cell function. These results suggest a cellular model where the Hsp40/60/70 
machinery is responsible for hindering the aggregation of most hard-to-fold proteins 
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while Hsp90 assists in the maturation of a select set of clients in an ATP-dependent 
fashion, potentially aided by its inherent anti-aggregation properties.  
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CHAPTER I 
 
Introduction 
 
This work was previously submitted for publication as: 
Natalie Wayne*, Parul Mishra*, and Daniel N. Bolon. (Submitted) Hsp90 and Client 
Protein Maturation. Methods in Molecular Biology.  
 
*These authors contributed equally to this work.  
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Hsp90, as with most heat shock proteins, was initially identified from changes in 
transcriptional pattern (1) and relative translational rate (2) upon shifting cells to elevated 
temperature. Hsp90 is named for its induction in response to temperature stress as well as 
its molecular weight of approximately 90 kilodaltons. Elevated temperature challenges 
the ability of proteins to fold efficiently, placing an elevated burden on cellular 
chaperones. In response to elevated temperature and many other stressful conditions, 
eukaryotes induce expression of the heat shock factor 1 (HSF1) transcription factor that 
in turn up-regulates expression of chaperones including Hsp90 (3). Many eukaryotes 
including budding yeast and humans have two genes encoding Hsp90 that encode nearly 
identical amino-acid sequences, one of which is constitutively expressed, while the other 
is HSF1 inducible (4). The constitutive expression level of Hsp90 under non-stress 
conditions is very high and Hsp90 is one of the most abundant proteins in the cell, 
accumulating primarily in the cytosol (5). The high expression level of Hsp90 in the 
absence of stress is consistent with its requirement for the activity of many critical signal 
transduction clients in eukaryotes. Hsp90 is essential for viability in eukaryotes (4). In 
bacteria, which lack the wealth of signal transduction proteins present in eukaryotes, 
Hsp90 knockouts are viable (6).  
 
The Hsp90 chaperone is highly conserved in eukaryotes both at the level of 
amino-acid sequence and biochemical function. The Saccharomyces cerevisiae and 
human Hsp90 proteins are 59 % identical in amino acid sequence alignments. The 
3 
 
 
 
conservation of Hsp90 in eukaryotes extends to the functional level as S. cerevisiae with 
both endogenous Hsp90 genes knocked out can be rescued by expression of human 
Hsp90 (7). Hsp90 serves as a protein interaction hub, binding to about 10 % of the yeast 
proteome (8) including many co-chaperones necessary for client maturation. The 
observation that human Hsp90 complements S. cerevisiae knockouts indicates that 
essential elements of this hub are evolutionarily conserved. Consistent with the functional 
conservation of Hsp90, steroid hormone receptors that are not natural to S. cerevisiae 
function in an Hsp90-dependent manner when introduced into yeast (7).  
 
Hsp90 contains three domains: the N-terminal (N) domain, middle (M) domain, 
and the C-terminal (C) domain (Figure 1.1). Crystal structure analysis of complexes 
between the N-domain of yeast Hsp90 and either ADP or ATP identified an adenine 
nucleotide binding site homologous to the ATP-binding site of the DNA gyrase B (9-11). 
Although fully able to bind ATP, isolated N-domain Hsp90 constructs have negligible 
ATPase activity indicating the involvement of other domains in the ATPase cycle. 
Several conserved amino acids in the N-domain make up a molecular “lid” that closes 
over the nucleotide-binding pocket in the ATP-bound, but not ADP-bound, state (12). 
Structural and biochemical studies demonstrate that Hsp90 is a “split” ATPase with 
catalytic amino acids from both the N (E33) and M (R380) domains in the same molecule 
contributing to hydrolysis (10, 13, 14). The C-domain forms a stable dimer (15).  
 
Figure 1.1. Crystal structure of Hsp90 dimer (10).
Hsp90 is a homodimeric protein consisting of an N-terminal nucleotide binding domain, 
middle domain, and C-terminal dimerization domain. 
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The activation of client proteins by Hsp90 relies on the opening and closing of a 
dimeric “molecular clamp” by transient association of the N-domains (Figure 1.2) and is 
directly coupled to the ATPase cycle of Hsp90 (16-19). Recent tour-de-force structural 
studies have revealed that flexible hinges between all three domains enable Hsp90 to 
adopt dramatically different three-dimensional conformations (10, 17, 20, 21). In the 
open conformation, Hsp90 first binds ATP in a fast reaction followed by a slow 
formation of the first intermediate, possibly where the so-called ATP lid is released from 
contact with the N-terminal segment. The N-domains of Hsp90 can then dimerize and 
subsequent rearrangements in the N to M domain contacts lead to the closed, ATPase 
active state. Following the hydrolysis of ATP, the products (ADP and Pi) are released and 
Hsp90 returns to the open state. Importantly, the structural changes are large and are the 
rate limiting steps in the ATPase cycle (12). 
 
A recent study found that a conformational equilibrium exists between the three-
states (ATP, ADP, apo) that is not irreversibly determined by the presence of nucleotide 
(19). Nucleotide binding was found to provide modest stabilizing energy to bias the 
equilibrium toward the corresponding conformational state. Comparison between 
Escherichia coli, yeast, and human Hsp90s identifies evolutionary adaptations to the 
conformational equilibrium between species to meet the particular client protein and 
metabolic environment of the organism.  
Figure 1.2. Model of the ATPase driven conformational cycle of Hsp90 that leads to 
client maturation. 
In addition to client and ATP, numerous co-chaperones bind to Hsp90 and influence its 
chaperone activity. Many of these Hsp90 binding interactions are inter-dependent. The 
nucleotide-bound state of Hsp90 influences the binding of both co-chaperones and 
clients. 
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Isolated Hsp90 is a slow ATPase, ranging from about 1 min-1 for yeast Hsp90 to 
about 0.1 min-1 for human Hsp90. Mutation of either of the catalytic amino acids of 
Hsp90 (E33 or R380) impairs ATPase activity and prevents yeast viability when present 
as the sole copy of Hsp90. However, Hsp90 point mutations that perturb the ATPase 
activity from 2 to 400 % of the wild-type level can support yeast growth under non-
stressful conditions (16). Thus, cell viability can tolerate a wide range of Hsp90 ATPase 
levels.  
 
The open and closed conformational rearrangements of Hsp90 during the ATPase 
cycle are coupled to the binding of many co-chaperones (22-24). Hsp90 interacts with 
more than twenty co-chaperones that coordinate the interplay between Hsp90 and other 
chaperone systems, regulate the ATPase activity of Hsp90, recruit Hsp90 client proteins, 
and contribute to the chaperone cycle through their enzymatic activities (12, 25). For 
example, the co-chaperone p23 and its S. cerevisiae homologue Sba1 preferentially bind 
to Hsp90 in the presence of ATP (26-28). Although not essential for Hsp90-dependent 
activation of client proteins, the interaction of p23/Sba1 with Hsp90 makes the activation 
process more efficient by stabilizing the state required for client-protein activation and 
slowing ATP turnover (23, 29-33). The Hsp90 co-chaperone Sti1 (Hop in mammals) is 
involved in the recruitment of client proteins to the Hsp90 system and is capable of 
arresting the ATPase cycle of Hsp90 to allow for client protein loading (34, 35). The 
kinase-specific Hsp90 co-chaperone Cdc37 also arrests the ATPase cycle of Hsp90 in the 
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client-loading phase by inhibiting the ATP-dependent N-domain dimerization (22, 24, 
36). To date, Aha1and its homolog Hch1 are the only co-chaperones known to activate 
the ATPase activity of Hsp90 (23, 37, 38) and therefore most likely interacts with an 
intermediate conformation of Hsp90 between the open and the closed state (17). 
 
Different co-chaperones preferentially interact with distinct conformations of 
Hsp90 allowing them to exert temporal control over conformational changes within the 
Hsp90-client complex (39). Asymmetric complexes between Hsp90 and co-chaperones 
allowing for interaction with multiple co-chaperones simultaneously have recently been 
identified (39-41). How the interaction of Hsp90 with its co-chaperones guides its 
recognition of client proteins and modulates its biochemical activities is an active area of 
investigation. 
 
Hsp90 has a unique ATP binding site and the discovery of small-molecule 
inhibitors that specifically inhibit Hsp90 has provided useful research tools that also show 
promise as anti-cancer therapeutic agents. Hsp90 inhibitors were originally uncovered 
from a natural product screen for compounds that reversed the transformed phenotype of 
the v-src oncogenic kinase. One of the natural products from this screen, geldanamycin 
(GA) was found to bind specifically to Hsp90 and inhibit its ability to chaperone v-src 
(42). GA binds to the adenine nucleotide binding pocket of Hsp90 suggesting it acts by 
blocking the binding of nucleotides to Hsp90 (9, 43). While Hsp90 function is essential 
11 
 
 
 
for the viability of healthy cells, cancer cells tend to have a higher level of Hsp90-
dependent clients and a higher required level of Hsp90 activity. For many types of cancer 
there appears to be a therapeutic window where cancer cells can be preferentially 
impacted by Hsp90 inhibition compared to healthy cells. The medical interest in Hsp90 
has spurred the synthesis of many small-molecule inhibitors as drug candidates (44). 
 
Hsp90 is a specialized molecular chaperone that is required for the maturation of 
a limited set of clients. Many newly synthesized proteins require general molecular 
chaperones including Hsp60 (GroEL in bacteria), Hsp70 and Hsp40 in order to fold 
properly, but only a small fraction of these rely upon Hsp90. The limited proteins that 
require Hsp90 to mature to their active state are referred to as Hsp90 clients. These 
Hsp90 clients fall into three main categories: protein kinases, steroid hormone receptors, 
and non-signal transduction clients (Table 1.1). Within each greater client class, research 
has revealed important aspects of the mechanism of Hsp90-mediated client maturation, 
yet the molecular mechanism by which Hsp90 binds to and activates clients remains 
largely a mystery. 
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Table 1.1. Classes of Hsp90 Clients. 
 
Client Class Example Clients Co-chaperones References 
 
Steroid Hormone Progesterone & FKBP51, FKBP52,  (45) 
Receptors Glococorticoid Receptors Hop, p23 
Kinase v-src, B-Raf Cdc37, Hop, p23 (42, 46) 
Non-Signal Transduction 
  CFTR CFTR Aha1 (47-49) 
  Telomerase Telomerase p23 (50) 
  Antigen Presentation MHC peptide loading   (51, 52) 
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Steroid hormone receptor Hsp90 clients 
Steroid hormone receptors are a class of transcription factors that are activated by 
binding to steroid agonist and were some of the first proteins actively studied as Hsp90 
clients. In 1984, Baulieu and colleagues reported that monoclonal antibodies raised 
against progesterone receptor (PR) recognized a 90 kilodalton protein that tightly 
associated with apo-receptor, but not steroid-bound receptor (53), properties that 
indicated a regulatory role for the 90 kilodalton protein. Soon after, Pratt and colleagues 
reported that monoclonal antibodies raised against glucocorticoid receptor (GR) were 
capable of immuno-isolating the receptor as well as a 90 kilodalton protein that cross-
reacted with antibodies raised against Hsp90 (54); thus identifying Hsp90 as a steroid 
hormone receptor chaperone.  
 
Hsp90 was found to bind strongly to the apo-form of many other steroid-hormone 
receptors including the estrogen and androgen receptors; however some receptors such as 
those for retinoic acid and thyroid hormone showed little or no affinity for Hsp90 (55-
58). Different DNA binding properties in the absence of steroid agonist were noted for 
Hsp90-dependent and Hsp90-independent receptors in cell-free expression systems (55). 
In the absence of steroid agonist, Hsp90-independent receptors were found to bind to 
target DNA in the presence and absence of Hsp90. In contrast, Hsp90-dependent 
receptors without steroid agonist only bound to DNA when Hsp90 was absent. In the 
absence of steroid agonist, Hsp90-dependent receptors were found in the cytoplasm while 
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Hsp90-independent receptors were found in the nucleus. At the time, these results led to 
the hypothesis that Hsp90 functions to repress steroid hormone receptors by sequestering 
them in the cytoplasm. However, it is now appreciated that Hsp90-dependent receptors 
require Hsp90 in order to bind to steroid. Steroid binding controls the activity of all 
steroid receptors and for Hsp90-dependent receptors this step requires Hsp90 activity. 
 
Co-immunoprecipitation (co-IP) experiments revealed many components of the 
Hsp90 chaperone complexes involved in receptor maturation and paved the way for in 
vitro reconstitution of the chaperone reaction. Glutaraldehyde cross-linking studies 
revealed that the stoichiometry of receptor-Hsp90 complexes was 1:2 indicating that a 
receptor monomer binds to an Hsp90 dimer (59). From immuno-isolation of steroid 
receptors expressed in cell-free expression systems it was discovered that receptor-Hsp90 
complexes contained a number of co-chaperones including Hsp70, p23 and Hop (60, 61). 
A combination of these three co-chaperones along with the general chaperone Hsp40 and 
Hsp90 were found to be sufficient to develop a purified chaperone system for the 
maturation of PR to the steroid-bound active form (62). 
 
Structural and biochemical approaches have shown that steroid hormone receptors 
bind steroid ligand in an internal cavity and indicate that Hsp90 remodels this cavity to 
provide a solvent-accessible path for the hormone to enter. X-ray crystal (63, 64) 
structures clearly show that steroid ligands bind to receptors in an internal cavity that is 
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completely inaccessible to solvent. Evidence for Hsp90 opening of this cleft comes from 
chemical modification studies that indicate modestly higher susceptibility of the steroid-
binding cavity in the Hsp90-bound form of apo-GR (65). While the mechanism by which 
Hsp90 opens the steroid binding cleft remains unknown, the data clearly indicates that 
isolated apo-GR and apo-PR are not able to bind to steroid agonist, but that when 
complexed with Hsp90 the binding to steroid becomes efficient (45). 
 
While much is understood about Hsp90 mediated steroid receptor maturation, 
many important aspects of the molecular mechanism remain open questions. It is clear 
that ATP hydrolysis by Hsp90 is required for efficient PR maturation (66). However, it is 
not clear how the ATPase driven conformational cycle of Hsp90 leads to opening of the 
steroid-binding cavity. What are the molecular interactions that cause apo-receptor to 
bind to Hsp90, Hsp90 to catalyze steroid binding, and steroid-bound receptor to 
dissociate from the chaperone complex? These questions are challenging to answer 
because of the dynamic nature of the Hsp90 conformational cycle, but may be addressed 
by structural and biochemical approaches that trap individual steps in the process. 
 
Kinase clients of Hsp90 
The oncogenic v-src kinase was first shown to bind to Hsp90 through co-IP 
analysis (67), but it was not clear that Hsp90 was required for v-src kinase activity until it 
was reported that the natural compound GA prevents v-src activity indirectly by 
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inhibiting Hsp90 (42). When v-src is expressed in the presence of GA, it accumulates in 
an inactive form indicating that Hsp90 is required for the maturation of v-src to an active 
form. In addition, treatment of cells with GA causes an increase in the proteosome 
mediated degradation rate of v-src and a decrease in the steady-state v-src level (68). 
Thus, Hsp90 is required for the maturation of v-src kinase to an active form and also 
protects v-src from degradation. 
 
The maturation of kinases mediated by Hsp90 requires co-chaperones including 
the kinase-specific co-chaperone Cdc37. Cdc37 was originally identified in a screen for 
genes required for cell cycle progression (69). Genetic evidence for a functional 
interaction between Cdc37 and Hsp90 came from studies showing that either mutations in 
Cdc37 or a reduction in the level of the yeast Hsp90 protein suppresses the lethality of v-
src over-expression (70, 71). Mutations in Hsp90 and Cdc37 were also found to 
exacerbate a defect in the Drosophila melanogaster sevenless receptor tyrosine kinase 
(72). Thus, Hsp90 and Cdc37 are both involved in the maturation of these model kinases. 
A physical connection between Cdc37 and Hsp90 was first indicated by co-IP analysis 
with the cyclin dependent kinase CDK4 (73). Both Hsp90 and Cdc37 were found to 
associate with CDK4 during co-IP analysis with an anti-CKD4 antibody suggesting there 
may be a direct mechanistic link between Hsp90 and Cdc37 in chaperoning kinases.  
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The direct interaction between Cdc37 and Hsp90 has recently been confirmed and 
described in atomic detail through structural analyses. Comparison of full-length yeast 
Hsp90 to truncated Hsp90 constructs indicated that the isolated Hsp90 N-domain was 
primarily responsible for mediating binding to the C-terminal domain of human Cdc37 
(24). Co-crystallization of these domains revealed the atomic details of this interaction 
(24). More recently, Pearl and colleagues have successfully purified a homogenous 
complex of human Cdk4 and Cdc37 along with Hsp90 from the insect Spodoptera 
frugiperda expression system and analyzed the structure of this complex by negative 
stain electron microscopy (21). This tour de force work indicates that the kinase-loaded 
complex consists of an Hsp90 dimer bound to single copies of Cdc37 and Cdk4. The 
observed electron density can be well fit with a structural model where Cdc37 binds to 
the Hsp90 N-domain and Cdk4 binds to the Hsp90 M-domain. Biochemical analyses of 
Cdk4-Cdc37 complexes in the absence of Hsp90 indicate a stoichiometry of one kinase to 
two Cdc37 molecules (21). The biochemical and structural data are consistent with an 
ordered model where a dimer of Cdc37 initially binds to kinases and subsequent binding 
of this complex to Hsp90 results in the release of one Cdc37 molecule.  
 
The association of human Cdc37 with yeast Hsp90 observed biochemically and 
structurally (24) is consistent with the high amino acid conservation of Hsp90 between 
these two species. This conservation is also apparent at a functional level as metazoan 
Cdc37 (from flies) is capable of rescuing robust growth of S. cerevisiae made unhealthy 
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by a point mutant in the yeast Cdc37 (72). Unlike Hsp90, the amino acid sequence of 
Cdc37 is divergent from yeast to humans with only 17 % sequence identity after 
alignment. Of note, yeast Cdc37 binds to yeast Hsp90 with about 100-fold weaker 
affinity than human Cdc37 (36), indicating that while qualitative Cdc37 function may be 
similar across eukaryotes, the interaction details are quantitatively distinct. 
 
The Hsp90 and Cdc37 chaperones stabilize the cellular accumulation of many 
kinases. Indeed, the observation that Hsp90 inhibition can lead to decreased cellular 
levels of client kinases has become a convenient screen to identify Hsp90-dependent 
kinases. In mammalian cells, inhibition of Hsp90 activity resulted in reduced levels of 80 
out of 105 kinases analyzed (74). A recent study also found that more than 50 % of the S. 
cerevisiae kinome was affected by the loss of functional Cdc37 (75) confirming the 
importance of a functional Hsp90:Cdc37 chaperone complex for the stability of cellular 
protein kinases. 
 
Recent efforts have described the minimum chaperone requirements for the 
maturation of a kinase in vitro.  Arlander et al. identified a five protein system for 
chaperoning the Chk1 kinase in vitro that consisted of Hsp90, Hsp70, Hsp40, Cdc37 and 
CK2 (46). The in vitro chaperone systems for kinases and steroid hormone receptors 
differ in their co-chaperone requirements and sensitivities, indicating the influential role 
that co-chaperones play in the client maturation process (62, 76). As with steroid 
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hormone receptors, the in vitro chaperone system for kinases provides a promising route 
to carefully analyze the client maturation process in detail. 
 
Non-signal transduction Hsp90 clients 
Recent evidence indicates that Hsp90 is involved in the maturation of active 
telomerase. The catalytic core of telomerase consists of a protein component (TERT) and 
a template RNA (TR). Chaperones were originally implicated in the maturation of 
telomerase from the observation that reconstitution of active telomerase from isolated 
TERT and TR was stimulated by increasing concentration of chaperones present in 
reticulocyte lysates (77). A two-hybrid screen revealed that the Hsp90 co-chaperone p23 
interacted with TERT and co-IP analyses revealed that both Hsp90 and p23 are involved 
in complexes with telomerase in mammalian cells (77). More recent biochemical 
dissections of telomerase function indicate that the interplay between Hsp90 and p23 
influences the dynamics of telomerase binding to telomeres (78). Hsp90 activity in vivo is 
important for the proper maintenance of telomeric DNA length that decreases when 
Hsp90 activity is impaired or when Hsp90 is over-expressed (50, 79).  
 
Hsp90 can bind to antigenic peptides and has been implicated in the delivery of 
these peptides to major histocompatability complexes (MHCs). Hsp90 was first 
connected with antigen presentation from analyses of antigens in tumors that could confer 
immunity in syngenic recipients (80). Fractionation studies revealed that Hsp90 from the 
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tumors was important in the development of immunity (81, 82). Cellular studies indicated 
that antigenic peptides complexed with Hsp90 are loaded on to MHC class I with much 
higher efficiency than free peptides (51), which may otherwise be prone to rapid 
degradation. In addition, the delivery of peptides to MHC class II proteins is reduced 
upon treatment of cells with Hsp90 inhibitors (52). The molecular details of Hsp90 
involvement in antigen presentation are a current area of active investigation. 
 
In addition to soluble proteins, Hsp90 has recently been implicated in the 
maturation of the Cystic Fibrosis Transductance Regulator (CFTR), an integral 
membrane protein. Hsp90 was originally implicated in CFTR maturation from the 
observation that treatment of mammalian cells with the Hsp90-specific inhibitors 
prevented newly synthesized wild-type CFTR from transitioning to the maturely 
glycosylated cell-surface form (47). Cystic fibrosis-causing mutations in CFTR, 
including the most commonly occurring – deletion of a phenylalanine codon ( F508), 
cause defective folding and export of CFTR from the ER (83). Immunoprecipitation of 
wild-type and F508 CFTR followed by mass spectrometry revealed that Hsp90 and 
many co-chaperones exhibited differential binding for wild-type and mutant CFTR (48). 
RNA interference screening of these co-chaperones demonstrated that silencing of the 
Hsp90 co-chaperone Aha1 rescued cell-surface expression and chloride ion transport of 
F508 CFTR (48). Recent biochemical analyses indicate that Aha1 associates with 
F508 CFTR nearly twice as much as with wild-type CFTR (49). The observation that 
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reducing the association of F508 CFTR with Aha1 corrects the function of this anion 
channel provides a promising avenue for the development of therapeutics to treat cystic 
fibrosis.  
 
Hsp90 can function as a promiscuous anti-aggregation chaperone in vitro for a 
large variety of hard-to-fold proteins, but it appears that Hsp90 is not required for the 
folding and solubility of most proteins in cells (84). Following the discovery that Hsp90 
expression increased in response to conditions that stress protein folding, a number of 
studies examined the capacity of Hsp90 to assist in the folding of proteins that were 
difficult to fold on their own including citrate synthase (CS), amyloid beta, p53, and the 
nucleotide binding domain of CFTR (CFTR-NBD1) (85-88). The ability of Hsp90 to 
suppress protein aggregation in vitro often does not require ATP (88-90).  In contrast 
both steroid hormone receptors and kinase clients of Hsp90 are dramatically impaired by 
mutations that destroy ATPase activity or by competitive inhibition of the ATP binding 
site with drugs (42, 66). Thus, the anti-aggregation properties of Hsp90 do not seem to 
require the same ATPase driven Hsp90 conformational cycle that is implicated in the 
maturation of kinases and steroid hormone receptors. Multiple chaperones in addition to 
Hsp90 are capable of providing anti-aggregation properties in cells providing a possible 
explanation for the observation that the general anti-aggregation properties of Hsp90 do 
not appear to be important in cells. 
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Questions addressed in this thesis 
 Molecular chaperones are involved in many different cellular pathways including: 
1) the folding and maturation of client proteins 2) the prevention of protein mis-folding 
and aggregation 3) the destruction and proteolysis of proteins that are unable to reach 
their mature state. As mentioned previously, Hsp90 is required for the maturation of 
numerous kinases (8) and steroid hormone receptors (91). Hsp90 has also been shown to 
function as a promiscuous anti-aggregation chaperone in vitro (85-88). More recently, 
Hsp90 has been shown to play a role in proteasome-mediated degradation of abnormal 
proteins through interactions with quality-control ubiquitin ligases such as CHIP (92). 
This thesis focuses on the role of Hsp90 in the maturation of client proteins and in the 
prevention of protein mis-folding and aggregation. 
 
 In the subsequent chapters, I will address the following questions: 1) How does 
Hsp90 dimerization contribute to its function in cells? 2) Is the ATPase activity of Hsp90 
required for maturation of kinases and steroid hormone receptors in vivo? 3) Is net charge 
required for chaperone-mediated protein solubility? 4) Why does Hsp90 anti-aggregation 
activity in vitro function in the absence of ATP, but in vivo function demonstrates 
absolute requirement for ATPase activity? 
 
 Hsp90 is predominately dimeric at physiological concentrations but can dissociate 
into monomers on the same time-scale as ATP hydrolysis. While the chaperone cycle of 
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Hsp90 has been examined extensively, the role dimerization in Hsp90 function in cells 
was previously unknown. Truncation of the C-terminal dimerization domain of Hsp90 
results in monomeric Hsp90 constructs that do not support yeast viability (93, 94). 
However, the C-domain may contribute other functional properties to Hsp90 in addition 
to dimerization. NM constructs of yeast Hsp90 that lack the C-domain were found to 
have a concentration-dependent specific ATPase activity suggesting they can mediate 
weak dimerization in the absence of the C-domain (93, 95). These studies suggest that 
Hsp90 monomers may be inactive for ATP hydrolysis. Yet heterodimers made up of one 
full-length Hsp90 subunit and one C-domain were found to have about 30 % of wild-type 
ATPase activity (93) which is within the range of reduced Hsp90 ATPase activity 
previously found to support yeast viability (16). These observations indicate that a full-
length Hsp90 monomer is required to test the role of dimerization in Hsp90 function in 
cells. 
 
In Chapter III, I designed and analyzed the function of a full-length monomer 
(NMCC) in yeast cells. NMCC Hsp90 had significantly reduced ATPase activity and was 
unable to support yeast viability as the sole copy of Hsp90. It was also unable to activate 
the Hsp90 client proteins GR and v-Src in yeast cells indicating that dimerization of 
Hsp90 is required for in vivo function. By forcing NMCC Hsp90 to dimerize by adding a 
C-terminal coiled-coil dimerization domain to the C-terminus, I was able to rescue the 
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ATPase and growth defects of monomeric Hsp90. This indicates that NMCC Hsp90 is 
defective purely because it is monomeric.  
 
Homo-oligomeric proteins have numerous functions in cells; however, co-
expression of homo-oligomeric proteins often results in the formation of cross-oligomers 
with unanticipated activity. The ability to restrict cross-oligomerization is crucial for the 
investigation of homo-oligomeric proteins, such as Hsp90, in cells. Chapter IV presents a 
modular approach to control cross-oligomerization using an additional coiled-coil 
dimerization domain fused to the C-terminus of Hsp90 (referred to as NMCcoil). This 
super-stabilization strategy prevented cross-oligomerization and was compatible with 
Hsp90 function in yeast cells. Contrary to previous models of Hsp90 function, the C-
domain dimer was recently found to open and close with fast kinetics with the C- and N-
domain dimerizations being anticorrelated (18). The ability of super-stabilized NMCcoil 
dimers to function fully in vivo suggests that any opening and closing of the C-domain 
dimer is not required for Hsp90 function. 
 
Super-stabilized NMCcoil Hsp90 was then used to investigate the role of ATP 
hydrolysis in Hsp90 function in yeast cells. Hsp90 mutations that prevent ATP binding 
(D79N) or hydrolysis (E33A) were previously identified in vitro and found to be 
incapable of supporting yeast viability (11, 96). While these results suggest that ATP 
hydrolysis by Hsp90 is critical for in vivo function, the role of ATP hydrolysis in client 
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protein maturation by Hsp90 had not previously been determined. In Chapter IV, I tested 
the ability of super-stabilized ATPase-deficient dimers to support that maturation of an 
Hsp90 client kinase (v-src) and steroid horomone receptor (GR). Both binding and 
hydrolysis of ATP by Hsp90 were found to be required for efficient maturation of kinase 
and steroid hormone receptor client proteins in yeast cells.  
 
In Chapter V, I describe one mechanism by which Hsp90 can prevent protein mis-
folding and aggregation. In mis-folded states, hydrophobic side-chains become 
increasingly exposed to solvent. Mis-folded proteins frequently aggregate in an energetic 
effort to bury these exposed hydrophobic surfaces. In contrast to hydrophobic effects, 
charged amino acids have been shown to increase proteins solubility (97). Analysis of net 
charge of three chaperones with anti-aggregation activity (Hsp90, Hsp70, and Hsp33) 
indicates they are all characterized by a high net charge that is evolutionarily conserved. 
In Hsp90, the negative charge is concentrated in the acid-rich charged linker (CL) and C-
terminal extension (CX). The combined deletion of the CL and CX ( CL CX) 
dramatically impaired the ability of Hsp90 to suppress the aggregation of CFTR-NBD1 
and CS. Importantly, addition of an acid-rich region with a distinct amino acid sequence 
to CL CX Hsp90 efficiently rescued anti-aggregation activity. These results indicate 
that the net charge of Hsp90, and not sequence-specific features, contributes to its anti-
aggregation activity in vitro. 
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Why does Hsp90 anti-aggregation activity in vitro function in the absence of 
ATP, but in vivo function demonstrates absolute requirement for ATPase activity? In 
Chapter VI, I discuss preliminary experiments attempting to address this apparent 
contradiction. Anti-aggregation deficient CL CX Hsp90 which maintains wild-type 
ability to hydrolyze ATP provides a useful separation of function mutant to address this 
controversy in vivo. I have shown that CL CX Hsp90 is able to support yeast growth at 
25 °C but not under stressful conditions (37 °C). However, CL CX accumulation is 
reduced compared to wild-type under stressful conditions. At this time, I cannot 
distinguish growth defects from expression level defects. In an effort to determine 
whether Hsp90 anti-aggregation activity is ATP-independent in vivo, I co-expressed 
CL CX Hsp90 with an ATP-binding deficient Hsp90 mutant (D79N) that was found to 
maintain in vitro anti-aggregation activity. D79N Hsp90 was unable to rescue the growth 
defect of CL CX Hsp90 indicating that the ATP-independent anti-aggregation activity 
is not sufficient to support yeast growth. Importantly, the growth defect observed for 
CL CX is not a dominant effect as co-expression of wild-type Hsp90 was able to 
efficiently rescue cell growth. My findings thus far are consistent with a model where 
Hsp90 assists in the maturation of select clients in an ATP-dependent fashion aided by its 
inherent anti-aggregation properties.  
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CHAPTER II 
 
Methods 
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Plasmid construction 
All Hsp90 constructs used in these studies were generated from the yeast HSP82 
gene. To aid in protein purification and Western blot detection, a 6xHis tag 
(GGHHHHHHGGH) was appended to the N terminus of Hsp90 constructs. Constructs 
were cloned into pACYC for bacterial expression and into p414GPD for expression in 
yeast. In Chapter 6, NMCcoil and D79Ncoil were cloned into p413GPD for co-
expression with CL CX 414GPD. Standard PCR techniques were used to generate all 
Hsp90 mutants. To generate super-stabilized Hsp90 dimers, a GCN4-based coiled-coil 
computationally optimized for stability (98) was inserted after amino acid 678 of the 
HSP82 gene resulting in the following protein sequence 
(I678GGGTSSVKELEDKNEELLSEIAHLKNEVARLKKLVGERTGD679). We refer to 
constructs containing this coiled-coil with the suffix coil. In addition, we refer to full-
length Hsp90 containing the N, M and C-domains as NMC to distinguish it from 
truncations containing only the C-domain. Thus, Ccoil refers to the C-domain appended 
with the coiled-coil and NMCcoil represents full-length constructs with the coiled-coil 
appended. 
 
The C-domain of Hsp90 contains amino acids 542-709. Single chain constructs of 
the C-domain were constructed with amino acids 537-680 from HSP82 followed by the 
glycine-rich linkers outlined in Figure 3.2 then by amino acids 542-709 from HSP82. The 
NMCC construct (Figure 3.1) contains amino acids 1-680 from HSP82 followed by the 
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15 amino acid linker in Figure 3.2 then amino acids 542-709 from HSP82. The 
NMCCcoil construct contains the coiled-coil sequence described above inserted after 
amino acid 678 of the second C domain of NMCC (Figure 3.10). 
 
Yeast kinases tested in Appendix I were generously provided by Michael Snyder 
(Stanford University) in a high copy URA3 expression vector, pEG(KG), that produces 
GST fusion proteins under the control of the galactose-inducible GAL1 promoter (99). 
pEG(KG) also contains an N-terminal 6xH tag to make the resulting GST-6xH-kinase 
fusion protein. The kinase Kin28 was amplified from yeast lysates and cloned into 
pEG(KG). For generating isolated kinase domain constructs, kinase domains were 
amplified from the full-length construct and cloned into pEG(KG).   
 
 
Protein production 
All Hsp90 constructs were expressed in BLR(DE3) cells induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside at 30 °C for five hours. Cells were harvested by 
centrifugation and resuspended in Wash Buffer (50 mM potassium phosphate pH 8.0, 300 
mM potassium chloride, 20 mM imidazole). Cell lysis was accomplished by treatment 
with lysozyme and sonication in the presence of DNAse1. After pelleting cell debris, 
lysates were incubated with Ni2+NTA agarose (Qiagen). After rinsing the nickel resin 
extensively with Wash Buffer, Hsp90 protein was competitively eluted with Elution 
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Buffer (200 mM imidazole, pH 7.5). Ethylenedinitrilotetraacetic acid (EDTA) was added 
to 10 mM to eluates which were subsequently dialyzed into Buffer A (20 mM potassium 
phosphate pH 6.8, 1 mM EDTA) for proteins in Chapters 3 and 4 or Buffer B (20 mM 
potassium phosphate pH 7.0, 1 mM EDTA) for proteins in Chapter 5. Protein samples 
were further purified by anion exchange chromatography using a Q sepharose HP column 
(GE) eluted with a linear gradient from 0 to 1 M potassium chloride in Buffer A or Buffer 
B. Protein samples in Chapter 3 were subjected to a final purification step of size 
exclusion chromatography using a Sephacryl S300 column (GE) in Buffer C (20 mM 
potassium phosphate, pH 6.8, 1 mM EDTA, 100 mM potassium chloride). Proteins were 
concentrated using Amicon Ultra concentrators (Millipore). Protein concentrations were 
determined spectroscopically using extinction coefficients (M-1cm-1) based on amino acid 
composition using the program Sednterp (Amgen) at 280 nm. Purified wild-type human 
CFTR-NBD1 encompassing amino acids 388-673 was a kind gift from the lab of Phil 
Thomas (University of Texas Southwestern – CFTR Folding Consortium). Purified 
citrate synthase from porcine heart was purchased from Sigma-Aldrich.  
 
Circular dichroism 
CD measurements were made on a Jasco A-810 spectropolarimeter equipped with 
a Peltier temperature control unit in a 1 mm pathlength cuvette. C domain spectra were 
acquired from 280 to 200 nm at a subunit concentration of 20 M in 20 mM potassium 
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phosphate, pH 7.0 at 25 °C while all other spectra were obtained at a concentration of 5 
M in Buffer A or Buffer B.  
 
Urea denaturation 
Equilibrium urea titrations in Chapters 3 and 4 were performed in Buffer C at 25 
°C. Protein denaturation was followed by monitoring the loss of ellipticity at 222 nm. 
Measurements at a subunit concentration of 2 M were made in a cuvette with a 1 cm 
pathlength using an autotitrator with a mixing time of 600 seconds (determined to be 
more than three times greater than the time constant for unfolding at the Cm). For urea 
titrations at a subunit concentration of 20 M, samples were manually mixed, allowed to 
equilibrate for 30 minutes and measurements made in a 1 mm cuvette.  
Urea denaturation experiments in Chapter 5 were performed with 3 M protein 
samples in a 0.3 cm pathlength cuvette. Samples were manually mixed, equilibrated for 
one hour, and changes in tryptophan fluorescence measured using a PTI QM-4SE 
spectrofluorometer with excitation set to 290 nm and emission scanned from 300 to 380 
nm at 1 nm/second.  
For all urea denaturation experiments, both the pre- and post-transition regions 
were fit to linear equations and used to replot the data as fraction unfolded or fraction 
folded using center-of-mass fluorescence (Cm) after correction for the fluorescence of the 
folded and unfolded states. The fraction unfolded or fraction folded plots were fit to two 
32 
 
 
 
state models with or without dimerization as appropriate and previously described (100, 
101) using the program Kaleidograph (Synergy Software). 
 
Analytical ultracentrifugation 
Equilibrium experiments were performed at 20 °C on a Beckman XLI instrument 
using absorbance optics and a Ti60 rotor. Absorbance profiles were taken at 12 hour 
intervals, and overlapping profiles were used as a criterion for equilibration. For the C 
domain constructs in Chapter 3, samples were analyzed at a subunit concentration of 50 
M in Buffer A with a rotor speed of 15,000 RPM and an equilibration time of 36 hours. 
For full-length constructs, samples were analyzed at a subunit concentration of 12 M in 
Buffer C (Chapter 3), Buffer D (50 mM Tris pH 7.5, 50 mM potassium chloride, 10 mM 
magnesium chloride – Chapter 4) or Buffer E (20 mM potassium phosphate pH 6.8, 150 
mM potassium chloride, 5 mM magnesium chloride – Chapter 5) with a rotor speed of 
8,000 RPM and an equilibration time of 36 hours. Absorbance profiles were fit to a single 
species model as previously described (102):  
c2(x) = c2(x0)exp[[M(1-V )
2/2RT](x2-x0
2)] 
where c2(x) is the concentration at a radial distance of x, x0 is a reference point, M is the 
molecular weight, V is the partial specific volume,  is the buffer density,  is the 
angular velocity, R is the universal gas constant, and T is the temperature. Data were fit 
in Kaleidograph using buffer density and V-bar values based on the buffer and amino 
acid composition and determined using the Sednterp program.  
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Analytical size exclusion chromatography 
100 L samples ranging in subunit concentration from 5-50 M were analyzed 
using Buffer C and a Superdex200 column (GE). Absorbance at 280 nm was used to 
monitor the elution profile. 
 
Enzymatically coupled ATPase assay 
ATP hydrolysis was enzymatically linked to NADH oxidation that was monitored 
spectroscopically (103). Hsp90 catalyzed ATP hydrolysis to generate ADP. Pyruvate 
kinase was used to convert ADP and phosphenolpyruvate to ATP and pyruvate. Lactate 
dehydrogenase was used to convert pyruvate and NADH to lactate and NAD with a 
corresponding drop in absorbance at 340 nm ( 340 = 6220 M
-1cm-1). ATPase assays were 
performed at 37 °C. Both Hsp90 protein samples (3 M) and ATPase components were 
pre-warmed then mixed. Using a Bio50 Spectrophotometer equipped with a Peltier 
temperature control unit (Cary) and a 1 cm pathlength cuvette, absorbance at 340 nm was 
measured at 15 second intervals (avoids photobleaching of NADH) for 10 minutes. Final 
concentration of ATPase components was 20 mM Tris pH 7.5, 5 mM magnesium 
chloride, 100 mM KCl, 1 mM ATP (Sigma), 0.17 mM NADH (Sigma), 0.67 mM 
phosphoenolpyruvate (Sigma), 0.01 mg/ml pyruvate kinase (Sigma), and 0.02 mg/ml 
lactate dehydrogenase (EMD Biosciences). The rate of NADH oxidation with 0.3 mM 
ADP was more than an order of magnitude greater than the highest rate observed with 
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Hsp90 demonstrating that ATPase components are not rate limiting. Rates were 
determined by fitting the change in absorbance versus time to a linear model, converting 
absorbance units to amount of NADH oxidized and normalizing to the concentration of 
Hsp90.  
 
Subunit mixing analysis  
Before measuring ATPase activity, mixtures of full-length and truncated Hsp90 
proteins were equilibrated in a volume of 90 L for 24 hours in Buffer A at 30 °C. After 
equilibration, 60 L of ATPase components were added and ATPase measurements made 
over 10 minutes at 37 °C. Final concentrations were: 5 M full-length Hsp90, 0-30 M 
truncated Hsp90. To determine the kinetics of NMCcoil and Ccoil subunit exchange, the 
equimolar experiment was repeated and ATPase activity measured as a function of pre-
equilibration time. The resulting data were fit to an exponential decay model:  
V=A+B*e-kt.  
For isolated full-length NMCcoil incubated at 30 °C, we found no detectable decay in 
ATPase rate after 48 hours. 
 
Fluorescent GA binding 
BODIPY-GA (BDGA) was synthesized as described (104). BDGA concentration 
was determined by absorbance in methanol using an extinction coefficient of 80,000 M-
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1cm-1 at 506 nm (105) and was in close agreement with the weighed mass of BDGA used. 
3 M BDGA was pre-incubated in assay buffer (20 mM Tris pH 7.5, 5 mM magnesium 
chloride, 100 mM potassium chloride, 0.01 % NP-40) with 10 mM dithiothreitol (DTT) 
for four hours at room temperature to convert GA to the high-affinity hydroquinone form 
(106). Samples were prepared in assay buffer with 5 mM DTT containing 1 M reduced 
BDGA and wild type or NMCC Hsp90 ranging from 0.1 to 3.3 M. These concentrations 
of Hsp90 and BDGA are both well above the 5 nM Kd determined for human Hsp90 and 
BDGA (106). Samples were equilibrated for 10 minutes at room temperature and 
fluorescence anisotropy measurements were made in a 0.3 cm pathlength cuvette on a 
PTI QM-4SE spectrofluorometer with excitation set to 488 nm and emission at 510 nm. 
 
 
Sole Hsp90 in yeast 
The haploid S. cerevisiae strains iG170Da (84) and ECU82a (107) are derivatives 
of W303 in which both endogenous Hsp90 genes, HSP82 and HSC82, are knocked out. 
In strain iG170Da, the temperature sensitive G170D mutant of HSP82 is chromosomally 
integrated and expressed from a GPD promoter. In strain ECU82a, wild type HSC82 is 
constitutively expressed from pKAT6, a URA3 marked 2 micron (high copy) plasmid that 
is amenable to negative selection. To test the ability of our Hsp90 constructs to support 
yeast viability, we generated them in p414GPD (108), a TRP1 marked CEN plasmid with 
a strong constitutive promoter. Lithium acetate was used to introduce our Hsp90 
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constructs into iG170Da and ECU82a and plating in the absence of tryptophan was used 
to select for transformants. For the iG170Da strain transformed with NMCD79N, it took six 
days for colonies to grow (for all other strains colonies were apparent after two days). 
Transformants were grown in liquid media lacking tryptophan to an OD600 of 0.7, 
serially diluted and plated under permissive or non-permissive conditions. All samples 
were grown and plated in synthetic media lacking tryptophan and with 2 % dextrose as a 
sugar source. For strain iG170Da, 25 °C was permissive and 37 °C was non-permissive. 
Strain ECU82a was grown at 25 °C, in the absence or presence of 5-fluoroorotic acid (5-
FOA) which selects for loss of the pKAT6 plasmid.  
 
For monitoring yeast growth at elevated temperature in Chapter 6, single colonies 
of ECU82a strains were selected from plates containing 5-FOA where the only copy of 
Hsp82 is the 414GPD plasmid-borne copy of interest. Liquid cultures were grown to an 
OD600 of approximately 0.5, serially diluted and plated on synthetic media lacking 
tryptophan with 2 % dextrose as a sugar source. Strains were then grown at the indicated 
temperature for 3-5 days. For monitoring growth at 37 °C in liquid culture, ECU82a 
strains containing only our plasmid-borne Hsp82 of interest (post-FOA swap), were 
grown for 48 hours with frequent dilution to sustain log-phase growth. Cell growth over 
time was measured using a Victor X5 multilabel plate reader (Perkin Elmer). The cell 
density once the cells had fully equilibrated to growth at 37 °C (after 24 hours) was fit to 
a linear curve to determine growth rate. 
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To determine the expression level of our Hsp90 constructs in ECU82a, liquid 
cultures in minimal media were grown to a cell density of 5×107 cells/ml determined with 
a hemacytometer. Cells were lysed by vortexing with glass beads and resuspension in 
SDS. Proteins from the lysis of 107 cells were separated by SDS-PAGE and the 
expression level quantified by Western blotting against the 6xH epitope tag. A standard 
curve was generated using purified Hsp90 added to lysates from cells that did not express 
any epitope tagged Hsp90. 
 
v-src assay 
Plasmid p316Galv-srcv5 was generated from p316v-src (107) and contains v-src 
with a C-terminal v5 epitope tag (GKPIPNPLLGLDST) under a galactose regulated 
promoter on a URA3 marked CEN plasmid. To analyze galactose induced expression of a 
non-Hsp90 client, the gene encoding the SspB protein (109) from Escherichia coli was 
cloned in place of v-src to create p316GalSspBv5. Lithium acetate was used to introduce 
p316Galv-srcv5 and p316GalSspBv5 into iG170Da cells and plating in the absence of 
uracil was used to select for transformants. To these cells we introduced our Hsp90 
constructs on p414GPD plasmids. On plates, cells were grown with dextrose as the sugar 
source to prevent v-src expression. Liquid cultures were grown in synthetic raffinose 
media without uracil and tryptophan at 25 °C to a cell density of about 5×106 cells/ml. 
Cells were pelleted and resuspended in media with either 2 % raffinose or galactose as 
the sugar source. After 15 minutes at 38 °C (Chapter 3) or 39 °C (Chapter 4) (to 
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inactivate G170D Hsp90), cells were grown in a shaking incubator at 36 °C for five hours 
(Chapter 3) or  37 °C for six hours (Chapter 4). Cell pellets were collected by 
centrifugation, washed once with water and frozen at -80 °C. The frozen cell pellets were 
lysed by vortexing with glass beads in Src Lysis Buffer (50 mM Tris, pH 7.5, 5 mM 
EDTA, 0.2 mM sodium orthovanadate to inhibit dephosphorylation, 1 mM 
phenylmethanesulfonylfluoride) followed by addition of SDS to 2 %. Protein 
concentration in these SDS lysates was assessed using the BCA assay (Pierce). Samples 
(2 g protein) were subject to SDS-PAGE and phosphotyrosine levels quantified by 
Western blot analysis with antibody 4G10 (Upstate) in the presence of 0.1 % TWEEN20. 
The level of v-src was quantified (20 g protein/lane) with -v5 antibody (Invitrogen) 
and the level of Hsp90 was quantified (20 g protein/lane) with -HisG antibody 
(Invitrogen) by Western blot analysis. 
 
GR assay 
P2A/GRGZ (107) is a 2 micron ADE2 plasmid that contains rat glucocorticoid 
receptor expressed from the constitutive GPD promoter and the -galactosidase ( -gal) 
reporter under the control of three glucocorticoid response elements. We introduced 
P2A/GRGZ together with our p414GPD Hsp90 constructs into iG170Da cells. Cells were 
grown in synthetic dextrose media lacking tryptophan and adenine at 25 °C to a cell 
density of about 5×106 cells/ml. Cells were pelleted by centrifugation. Cultures were 
grown in a shaking incubator at 38 °C (Chapter 3) or 39 °C (Chapter 4) for fifteen 
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minutes (to inactivate G170D Hsp90) and then split in half. Deoxycorticosterone (DOCS) 
dissolved in ethanol was added to final concentrations of 0, 0.08, 0.4, 2, 10, or 50 M 
(final concentration of ethanol was 0.1 % in all cases). Cells were grown for a further 60 
minutes at 36 °C or 37 °C and collected by centrifugation. After washing once with 
water, cell pellets were frozen at -80 °C. Cells were lysed by vortexing with glass beads 
in Gal Lysis Buffer (100 mM potassium phosphate, pH 7.3, 2 mM magnesium acetate, 1 
mM PMSF). After removing cell debris, protein concentration in the lysates was 
determined using the BCA assay (Pierce). A total of 10 g of lysate was reacted for 15 
minutes in a total volume of 80 L of 1 mg/ml o-nitrophenyl-beta-D-galactoside (Sigma) 
in Gal Lysis Buffer. The reaction was stopped by adding 80 uL of 1 M sodium 
carbonate. Reporter activity was quantified by monitoring the absorbance at 420 nm. GR 
assays were repeated three times starting from fresh yeast colonies. One-tailed student T-
tests were used to compare the no-insert strain to the Hsp90 strains. To analyze GR 
levels, a FLAG epitope was introduced into P2A/GRGZ at the Nco site that is preceded 
by a polyglutamine repeat in GR. GR-FLAG levels were analyzed by Western blotting 
with -FLAG antibody (Sigma). GR-FLAG responded to DOCS stimulation in all of the 
mutants indistinguishable from untagged GR.  
 
Sequence-based analysis of charge conservation 
For the eukaryotic proteins Hsp90, Hsp70, Hsp60, and triosephosphate isomerase, 
protein sequences from the same six species were analyzed (Table 5.2). Predicted net 
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charge of the proteins at pH 7 was determined based on the amino acid composition using 
the program SEDNTERP (Amgen). For the bacterial heat shock protein Hsp33, protein 
sequences from six species representing three distinct phyla were analyzed (Table 5.2). 
To ensure that the charge analysis was not affected by the diversity of bacterial genomes, 
only sequences that maintained at least 20 % sequence identity to the remaining 
sequences were analyzed.  
 
In vitro aggregation assays 
CFTR-NBD1 experiments were performed essentially as previously described 
(88) except that native protein was used as the starting material. Right-angle light 
scattering was measured in a PTI QM-4SE spectrofluorometer in a temperature 
controlled 0.3 cm pathlength cuvette. Protein samples were degassed for twenty minutes 
at room temperature and aggregation was initiated by transfer to a cuvette prewarmed at 
37 C. Measurements were made as a function of time at a wavelength of 400 nm 
(excitation and emission) in CFTR buffer (100 mM Tris-hydrochloride pH 7.4, 0.385 M 
L-arginine, 10 mM DTT, 200 mM potassium chloride, 20 mM magnesium chloride) (88). 
Protein concentrations were 5 M Hsp90 and 1 M CFTR NBD1. CFTR-NBD1 
aggregation experiments were also attempted at varying concentrations of salt. However, 
CFTR-NBD1 aggregation in low salt buffers was too rapid to interpret data obtained 
under these conditions. All data were normalized to the light-scattering intensity for 
CFTR-NBD1 aggregation after twenty minutes at 45 C. 
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The solubility of Hsp90 constructs was monitored by light scattering under the 
same conditions, in the absence of CFTR-NBD1. The aggregation of Hsp90 variants on 
their own was also monitored by Native PAGE. Samples of 5 M protein in Buffer B 
were heated in a PCR machine for 5 minutes, cooled to room temperature, run on native 
PAGE (6 % acrylamide, 30 mM Hepes, 30 mM imidazole) and stained with Sypro Ruby 
gel stain (Invitrogen). 
 
Mixing experiments were performed by mixing 2.5 μM NMCcoil Hsp90 (110) 
and 2.5 μM CL CX Hsp90. Light scattering from the mixed sample was compared to 
that of CFTR-NBD1 in the presence or absence of 2.5 μM NMCcoil Hsp90 or 2.5 μM 
CL CX Hsp90. 
 
Aggregation of 0.075 μM CS was measured in the presence of 0.6 μM Hsp90 as 
described previously (85). Protein samples were degassed for forty minutes at room 
temperature and then right angle light scattering at a wavelength of 500nm was measured 
at 43 ºC in CS Buffer (40 mM HEPES pH 7.5, 1 mM MgCl2). The solubility of the 
Hsp90 constructs was monitored under the same conditions, in the absence of CS. Mixing 
experiments were performed by mixing 0.3 μM NMCcoil Hsp90 and 0.3 μM CL CX 
Hsp90. Light scattering from the mixed sample was compared to that of CS in the 
presence or absence of 0.3 μM NMCcoil Hsp90 or 0.3 μM CL CX Hsp90. All data 
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were normalized to the light-scattering intensity for CS aggregation after forty minutes at 
43 C. 
 
Analysis of protein aggregates 
To monitor the content of the aggregates formed by mis-folded CFTR-NBD1, 200 
L samples of CFTR-NBD1 in the presence and absence of Hsp90 were heated to 45 ºC 
for 20 minutes in a water bath. Polycarbonate centrifuge tubes (Beckman) were pre-
blocked with 10 mg/mL gelatin to prevent non-specific sticking then samples were 
pelleted at 17,000 rpm in a Beckman Optima TL Ultracentrifuge for 10 minutes. Pellets 
were washed with CFTR buffer and resuspended in SDS Loading Buffer. Samples were 
separated by SDS-PAGE, transferred to nitrocellulose, and analyzed by western blot for 
Hsp90 or CFTR-NBD1 (antibody was graciously provided by William Balch, Scripps 
Research Institute – CFTR Folding Consortium). To compare protein levels on the Hsp90 
and CFTR-NBD1 western blots, 10 % or 100 % load samples were added. 
 
Cellular accumulation of yeast kinases 
Yeast kinase pEG(KG) constructs were transformed into the haploid S. cerevisiae 
strain iG170Da wild-type Hsp90 414GPD or an empty 414GPD vector. Liquid cultures 
were grown in synthetic raffinose media without uracil and tryptophan at 25 °C to a cell 
density of about 5×106 cells/ml. Cells were pelleted and resuspended in media with 2 % 
galactose as the sugar source. After 15 minutes at 39 °C (to inactivate G170D Hsp90), 
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cells were grown in a shaking incubator at 37 °C for six hours. Cell pellets were collected 
by centrifugation, washed once with water and frozen at -80 °C.  
 
Frozen cell pellets were lysed by vortexing with glass beads in Kinase Lysis 
Buffer (50 mM potassium phosphate, pH 8.0, 300 mM potassium chloride, 0.5 % Tween-
20, 10 mM PMSF) followed by addition of SDS to 2 %. Protein concentration in these 
SDS lysates was assessed using the BCA assay (Pierce). The level of each kinase was 
quantified (20 g protein/lane) with -GST antibody (Santa Cruz Biotechnology) by 
Western blot analysis.  
 
Identification of peptide substrates for yeast kinases 
 GST-6xH-tagged kinases were expressed in iG170D cells at 25 °C. Cells were 
grown in synthetic raffinose media in the absence of uracil to a cell density of 1x107 
cells/mL then pelleted and used to inoculate one liter of synthetic galactose media. After 
kinases were expressed at 25 °C for six hours, cell pellets were collected by 
centrifugation and frozen at -80 °C. Cell lysis was accomplished by nitrogen 
decompression in Kinase Lysis Buffer. After pelleting cell debris, lysates were incubated 
with Co2+NTA agarose. After rinsing the cobalt resin extensively with Kinase Wash 
Buffer (50 mM potassium phosphate pH 8.0, 300 mM potassium chloride, 20 mM 
imidazole), kinases were competitively eluted with Kinase Elution Buffer (50 mM 
potassium phosphate pH 8.0, 300 mM potassium chloride, 250 mM imidazole). Purified 
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protein was dialyzed into Kinase Dialysis Buffer (50 mM Tris pH 7.5, 150 mM 
potassium chloride, 2 mM DTT). As a purification control, a non-kinase yeast protein 
(YIR027C, Dal1) was also purified as a GST-6xH fusion protein. 
 
Potential peptide substrates for each kinase were synthesized on amino-PEG 
cellulose membranes (MIT Biopolymers Laboratory). Membranes were first blocked with 
1 % bovine serum albumin in phosphate buffered saline (PBS) for one hour at 30 °C. 
Membranes were washed with PBS then incubated with 10 mL purified Dal1, 500 µCi γ-
32P[ATP], and 200 µL 1 mM ATP at 30 °C for 30 minutes. Membranes were washed for 
thirty minutes in PBS then exposed to a phosphor screen and scanned using a Typhoon 
FLA-9000 (GE). Signal was quantified using Multi Gauge (Fujifilm).  
 
Membranes were dephosphorylated at 30 °C for two hours using 400 units/mL 
Lambda Protein Phosphatase (NEB) with 1 mM manganese chloride in Kinase 
Dephosphorylation Buffer (50 mM HEPES pH 7.5, 100 mM sodium chloride, 2 mM 
DTT, 0.01% Triton X-100). After washing for 20 minutes in PBS, membranes were 
incubated with 10 mL purified kinase, 500 µCi γ-32P[ATP], and 200 µL 1 mM ATP at 30 
°C for 30 minutes, washed for thirty minutes in PBS then exposed to a phosphor screen 
and scanned using a Typhoon FLA-9000 (GE). Signal was quantified using Multi Gauge 
(Fujifilm). 
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Kinase assays 
To monitor phosphorylation of peptide substrates identified for each kinase, 200 
µM fluorescently-labeled peptide was mixed with 2 mM ATP, 0.2 mg/mL creatine 
kinase, 100 mM creatine phosphate in Kinase Assay Buffer (20 mM Tris pH 7.5, 100 
mM potassium chloride, 5 mM magnesium chloride, 10 mM DTT). The peptide mixture 
was then mixed with an equal volume of yeast lysate or purified kinase and incubated at 
30 °C for 30 minutes. An equal volume of Native Gel Loading Buffer (5 mM HEPES, pH 
7.5 and 20 % sucrose) was added and samples separated by native PAGE (6 % 
acrylamide, 30 mM Hepes, 30 mM imidazole). Gels were scanned using a Typhoon FLA-
9000 (GE) and the signal quantified with Multi Gauge (Fujifilm). 
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CHAPTER III 
  
Dimerization of Hsp90 is required for in vivo function 
 
This work was previously published as:  
 
Natalie Wayne and Daniel N. Bolon. (2007) Dimerization of Hsp90 is Required for In 
Vivo Function: Design and Analysis of Monomers and Dimers. The Journal of 
Biological Chemistry. 282(48), 35386-35395. 
 
 
Experiments in this chapter were primarily conducted by Daniel Bolon. I designed 
and completed the experiment to determine the stoichiometry of Hsp90 (wild-type and 
NMCC) binding to BDGA (Figure 3.4C). 
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Abstract 
Heat shock protein 90 (Hsp90) plays a central role in signal transduction and has 
emerged as a promising target for anti-cancer therapeutics, but its molecular mechanism 
is poorly understood. At physiological concentration, Hsp90 predominantly forms 
dimers, but the function of full-length monomers in cells is not clear. Hsp90 contains 
three domains: the N-terminal and middle domains contribute directly to ATP binding 
and hydrolysis and the C domain mediates dimerization. In order to study the function of 
Hsp90 monomers, we used a single-chain strategy that duplicated the C-terminal 
dimerization domain. This novel monomerization strategy had the dual effect of 
stabilizing the C domain to denaturation and hindering intermolecular association of the 
ATPase domain. The resulting construct was predominantly monomeric at physiological 
concentration and did not function to support yeast viability as the sole Hsp90. The 
monomeric construct was also defective at ATP hydrolysis and the activation of a kinase 
and steroid receptor substrate in yeast cells. The ability to support yeast growth was 
rescued by the addition of a coiled-coil dimerization domain, indicating that the parental 
single-chain construct is functionally defective because it is monomeric. 
 
 
48 
 
 
 
Introduction 
Among heat shock proteins, Hsp90 is unusual because it is not required for the 
proper folding of most cellular proteins (84), and instead is disproportionately linked to a 
select group of proteins required for receiving, transducing, and responding to 
environmental signals. The list of Hsp90 substrates continues to grow and includes over 
40 kinases (8) and many steroid hormone receptors (91). The molecular mechanism of 
Hsp90 activation of both hormone receptors and kinases remains to be determined. 
 
How does Hsp90 dimerization contribute to its function in cells? Structurally, 
Hsp90 contains an N-terminal domain that binds nucleotide, a middle domain, and a C-
terminal dimerization domain (Figure 3.1). Truncations of Hsp90 that lack the C-domain 
are largely monomeric (93) and do not support yeast viability (94). These results do not 
demonstrate that dimerization of Hsp90 is essential because the C-domain may contribute 
other functional properties in additional to dimerization. The deletion of a loop from the 
C-domain (582-601) that is largely solvent exposed (10) prevents yeast viability (94), 
suggesting that dimerization is not the only essential role of the C-domain. In addition, a 
point mutation (A587T) in this same loop impairs the chaperoning of GR in yeast (107). 
Because Hsp90 activity requires co-chaperones and Hsp90 binds promiscuously to about 
10 % of the yeast proteome (8), it is important to study Hsp90 function in cells where all 
endogenous binding partners are present. To rigorously test how dimerization affects 
Hsp90 function in cells requires a full-length Hsp90 monomer. 
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The ATPase activity of Hsp90 is required for cellular function, though the 
molecular mechanism that couples ATP hydrolysis to substrate activation is poorly 
understood. Dimerization of Hsp90 has been implicated in ATP hydrolysis. NM 
constructs of yeast Hsp90 lacking the C-terminal dimerization domain have 
concentration-dependent specific ATPase activity (93). These results indicate that the N 
and/or M domains can mediate weak dimerization that leads to increased ATPase 
activity. Consistent with this analysis, the disulfide cross-linking of truncated Hsp90 
constructs increases their ATPase activity (95). These studies raise the possibility that 
full-length Hsp90 monomers may be inactive for ATP hydrolysis. Studies with 
heterodimers made up of one full-length Hsp90 subunit and one C-domain, indicate that 
full-length/C-domain Hsp90 heteromers have about 30 % the ATPase activity of wild-
type (93), well within the 2 to 400 % range previously observed to support yeast viability 
(16). These observations have stimulated the current work to determine if Hsp90 
monomers are functional in cells. 
 
We have used a single-chain strategy to design a full-length NMCC Hsp90 
monomer (Figure 3.1) and analyzed its function in yeast cells. To our knowledge, this is a 
novel approach to making full-length monomers and relative to traditional strategies that 
mutagenize the dimer interface, has the advantage of stabilizing the dimerization domain  
Figure 3.1. Design strategy.
(A) Architecture of the Hsp90 gene and the dimeric protein structure. Hsp90 contains 
three domains referred to as N (N-terminal), M (Middle), and C (C-terminal). In the 
structural representation, these domains are colored blue-N, green-M, and red-C with 
lighter colors distinguishing the dimer subunit pictured on the left. (B) The stability to 
urea denaturation of the C domain is concentration dependent. At the low protein 
concentrations required to populate monomers, the stability of the C domain would be 
marginal. (C) NMCC strategy to design a full-length Hsp90 monomer with increased C 
domain stability.
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to denaturation. NMCC Hsp90 will provide a tool to further explore the biochemical 
properties of Hsp90 monomers and their role in the chaperone cycle. 
 
Results 
C domain has marginal stability to urea denaturation. 
The goal of our engineering efforts is to generate a natively folded full-length 
Hsp90 monomer that has one ATPase site. We considered traditional dimer disruption 
strategies, but were concerned that mutations at the dimer interface might destabilize the 
C domain causing it to mis-fold. To address this concern, we monitored the stability of 
the C domain. The stability of a protein is a measure of its capacity to tolerate 
destabilizing mutations and still fold (111). We analyzed the stability of the isolated C 
domain to urea-induced unfolding. In the absence of urea, the circular dichroism 
spectrum of the C domain has minima at 208 and 222 nm indicating that it forms a folded 
structure with significant helical content (Figure 3.3). We used CD to monitor the 
transition of the isolated C domain from folded to unfolded as a function of urea 
concentration (Figure 3.1B). The urea concentration midpoint (Cm) of denaturation 
increases with higher C domain concentration (2.38 M urea at 2 M and 2.74 M urea at 
20 M). The dependence of Cm on protein concentration indicates that dimerization and 
protein folding are coupled. At concentrations of Hsp90 (93) where monomers become 
populated (the midpoint of association is 60 nM), our results indicate that the C domain 
would be marginally stable to denaturation. Taking these observations into account, we  
Figure 3.2. Single-chain C-domains are increased in stability and monomeric. 
(A) Design of single-chain C-domain constructs with glycine-rich linkers to span the 
domains. In the ribbon diagram, spheres indicate the N terminus and C terminus of this 
domain. 27 Å is the distance that the linker needs to span in order to link the C terminus 
of one domain to the N terminus of the next domain. (B) All three single-chain 
constructs are increased in stability to urea denaturation compared to the wild-type 
C-domain. (C) Equilibrium analytical ultracentrifugation at 30 µM protein concentration 
demonstrates that C15C is monomeric. The theoretical distribution expected for a dimer 
is shown for comparison.
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decided upon a monomerization strategy that would enhance the stability of the C domain 
(Figure 3.1C). Duplication of the C domain in NMCC should both increase the stability 
of the C domain to denaturation and disfavor intermolecular association. Thus NMCC 
should have one ATPase site per molecule. 
 
Isolated single-chain C domain is stable and monomeric. 
With the aim of generating a single-chain C domain that is both monomeric and 
stable, we generated CC constructs separated by variable length glycine-rich linkers 
(Figure 3.2A). Based on the crystal structure of Hsp90, the flexible linkers need to span a 
distance of 27 Ǻ. While eight amino acids in a fully extended conformation can span this 
distance, previous single-chain studies have found that a greater number of amino acids is 
required to avoid strain and maximize stability (112). We made glycine-rich linkers of 
11, 15, and 19 amino acids based on a proteolytically stable loop in bacteriophage gene-
3-protein that had been used in a previous single-chain study (113). All three single-chain 
constructs (C11C, C15C, and C19C) expressed to high levels in E. coli, were readily 
purified, highly soluble and had CD spectra similar to the wild-type C domain (Figure 
3.3). At a subunit concentration of 2 M, we observe that C11C, C15C, and C19C all 
have increased stability to urea denaturation relative to wild type (Figure 3.2B). These 
results indicate that the effective concentration caused by the covalent single-chain 
linkages is greater than the concentration of wild-type protein (2 M).  
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The 15 amino acid linker (C15C) was the smallest link eliciting the greatest 
stability and was chosen for further analysis. The increased stability of C15C could be 
caused by either a high effective concentration of covalently linked subunits as designed, 
or from unanticipated oligomerization. To differentiate between these possibilities, we 
analyzed the solution oligomeric state of C15C using equilibrium analytical 
ultracentrifugation (Figure 3.2C). The distribution of C15C fit very well to a single 
species model with a molecular weight (40.1 kD) similar to the theoretical molecular 
weight of the C15C construct (37.4 kD). The residuals from the single species fit are 
randomly distributed indicating that higher order oligomeric species are not populated 
enough to be detected. The results of equilibrium analytical ultracentrifugation (AUC) 
demonstrate that C15C is monomeric in solution. This observation is further supported by 
the size exclusion chromatography profile of C15C that elutes as a monomer with a 
similar radius of gyration to the wt C domain dimer (Figure 3.3). The CD spectra (Figure 
3.3) and size exclusion profile of C15C is similar but not identical to the wild-type C 
domain most likely because of the truncation of an unstructured region (amino acids 681-
709) from the first domain in C15C. We find that the stability of C15C to urea 
denaturation is independent of protein concentration (Figure 3.3) indicating that protein 
folding is no longer coupled to oligomerization (unfolded single-chain monomers go to 
folded single-chain monomers with no change in oligomeric state).  
 
 
Figure 3.3. Biophysical properties of C domain constructs. 
(A) Circular dichroism spectra of wild-type and single chain constructs all have minima 
near 208 and 222 nm indicating significant helical secondary structure content. In the 
presence of high concentrations of urea most of this secondary structure content is lost 
as the proteins denature. (B) Stability of C15C is concentration independent, consistent 
with a transition from a folded monomer to an unfolded monomer with no change in 
oligomeric state. (C) Size exclusion chromatography of wild-type and C15C constructs. 
Wild-type has a radius of gyration consistent with a spherical dimer and C15C with a 
spherical monomer.
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Based on its design, the C15C domain should be monomeric when intramolecular 
C domain interactions outcompete intermolecular association. At very high 
concentrations it should be possible for intermolecular C15C association to occur. We 
can use the concentration dependent stability of the wild-type C domain to estimate the 
protein concentration that would be required for intermolecular association to 
energetically equal intramolecular interactions. Based on the concentration dependent 
stability of wild type C domain (Figure 3.1), we estimate that a concentration of 2 mM 
would be required to achieve the same Cm to urea denaturation as C15C. Thus, 2 mM 
represents the effective concentration brought about by the covalent linkage of C 
domains. Effective concentrations in the mM range have been reported for single-chain 
constructs of similar length (112). From this analysis, we predict that at a concentration 
of 2 mM the C15C construct will equally partition between monomers and dimers, but 
that at physiological Hsp90 concentration (approximately 10 M) C15C will be almost 
entirely monomeric. This analysis is supported by our observation that at 30 M, C15C is 
monomeric as determined by AUC  (Figure 3.2C). 
 
Full-length NMCC monomer design is deficient for ATP hydrolysis. 
In order to explore the function of full-length Hsp90 monomers, we generated an 
NMCC construct (Figure 3.1C) with the 15 amino acid linker between the two C 
domains. The single-chain C domain in NMCC should hinder dimerization, resulting in a 
molecule with single N and M domains - the location of ATP hydrolysis as well as 
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numerous interactions with co-chaperones and substrates (9, 10, 14, 21, 114). 
Equilibrium analytical ultracentrifugation was used to assess the oligomeric state of 
NMCC (Figure 3.4A). The radial distribution of NMCC at 12 M during centrifugation 
fits well to a single molecular weight species with a mass of 103 kD, similar to the mass 
of a monomer (99 kD). The residuals from the single species fit are randomly distributed 
indicating that higher order oligomers are not detected. We find that under identical 
centrifugation and concentration (12 M) conditions, wild type Hsp90 is dimeric (Figure 
3.5). These results demonstrate that the single-chain C domain effectively blocks 
dimerization in the full-length NMCC construct.  
 
How does blocking Hsp90 dimerization effect ATPase activity in vitro? Using an 
enzymatically coupled ATPase assay, we observed that NMCC was severely impaired for 
ATPase activity relative to wild-type Hsp90 (Figure 3.4B). The ATPase activity of 
NMCC was inhibited by GA, a small-molecule inhibitor with high specificity for Hsp90. 
These results indicate that the ATPase domain in NMCC can bind to both ATP and GA. 
To determine the fraction of NMCC molecules capable of binding to GA, we performed a 
stoichiometric binding experiment (Figure 3.4C). A concentration of fluorescently 
labeled BODIPY-GA of 1 M was used and Hsp90 concentrations of wild-type and 
NMCC were increased to determine the ratio of Hsp90 to GA where binding saturated. 
For both wild type and NMCC Hsp90, binding saturates at about 1.4 Hsp90 subunits to 1 
GA. Taking into account uncertainty in concentration determinations and possible non- 
Figure 3.4. Full-length NMCC construct is predominantly monomeric and is 
defective for ATP hydrolysis. 
(A) The distribution of 12 µM NMCC in equilibrium analytical ultracentrifugation fits 
well to a single species with the molecular weight of a monomer. The theoretical distri-
bution expected for a dimer is shown for comparison. (B) At 6 µM protein concentra-
tion, NMCC is more than 10-fold slower at ATP hydrolysis than wild type Hsp90 and 
can be inhibited with geldanamycin (GA) a specific inhibitor for the ATP binding site of 
Hsp90. (C) Stoichiometry binding experiment indicates that binding of Hsp90 to 
BODIPY-GA saturates at a ratio of approximately 1 GA molecule per 1 Hsp90 subunit 
for both wild type and NMCC Hsp90. (D) The specific ATPase activity of NMCC 
Hsp90 is concentration dependent.
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Figure 3.5. Equilibrium analytical ultracentrifugation of wild-type Hsp90. 
The radial distribution of protein at 12 µM fits well to a single species model with the 
molecular weight of a dimer.
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fluorescent contaminants in the BODIPY-GA preparation, these experiments indicate that 
both wild-type and NMCC are capable of high-affinity binding of 1 molecule of GA per 
Hsp90 subunit. These results indicate that the ATP binding site of NMCC is structured 
similarly to wild type Hsp90.  Consistent with the engineering strategy of NMCC, the 
single-chain C domain does not destroy the ATP or GA binding function of the N 
domain. 
 
Is the observed ATPase activity of NMCC from monomer species or a low 
proportion of dimer species? To differentiate between these possibilities, we monitored 
specific ATPase activity as a function of protein concentration (Figure 3.4D). The ratio of 
dimer:monomer species varies with concentration enabling the activity from monomer 
and dimer species to be assessed. For wild-type Hsp90, specific ATPase activity is 
independent of protein concentration indicating that dimers are the dominant molecular 
form over the concentration range tested (3-15 M). This result is consistent with the 
protein concentration being well over the dimer dissociation constant, previously 
measured as 60 nM for wild-type Hsp90 (93). In contrast, the specific ATPase rate of 
NMCC increases over the same protein concentration range. This result is consistent with 
NMCC monomers and dimers having different ATPase rates, and the ratio of NMCC 
dimers:monomers changing over the concentration range tested.  
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The linear increase in specific activity of NMCC indicates that these experiments 
do not saturate the dimer species over this concentration range, preventing the direct 
determination of the dimer dissociation constant. Assuming that the NMCC dimers have 
the ATPase activity of wild-type dimers, we estimate that NMCC has a dimer 
dissociation constant of 200 M under the conditions of the ATPase assay. This result is 
consistent with interactions between the N and M domains driving weak association of 
NMCC. Consistent with this interpretation, NM constructs show concentration dependent 
ATPase activity with similar apparent dimer dissociation constants (93). In addition, this 
dissociation constant for NMCC is about 10-fold tighter than the dissociation constant we 
estimate for the single-chain C domain alone which corresponds to a free energy of NM 
association of about 5 kJ/mol. Based on the ATPase activity at low NMCC concentration, 
we estimate the upper limit for monomer activity as 0.05 min-1, or 3% the rate of wild-
type Hsp90. 
 
Function of NMCC in vivo. 
Hsp90 is an essential gene in eukaryotes (4, 115, 116). Interestingly, Hsp90 point 
mutants with in vitro ATPase levels less than 2 % of wild-type can function to support 
yeast viability (16, 107). Therefore, we tested the ability of NMCC to support viability as 
the sole Hsp90 in yeast. Both NMCC and wild-type Hsp90 with N-terminal His6 epitope 
tags were constitutively expressed from a plasmid system previously shown to 
accumulate Hsp90 to near wild-type levels (117). These plasmids were introduced into 
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two yeast strains: one whose other source of Hsp90 was a temperature sensitive allele, 
and one whose other source of Hsp90 was encoded on a URA3 plasmid that can be 
swapped out using 5-FOA which is converted to the toxic fluoroorotidine monophosphate 
when the URA3 gene is expressed. Under conditions where active dimeric wild-type 
Hsp90 is present, expression of NMCC did not compromise cell growth in either strain 
(Figure 3.6). Under conditions that select for NMCC as the sole active Hsp90, both 
strains failed to grow (Figure 3.7).  
 
The failure to support growth could be due to low expression level of NMCC. To 
test this possibility, we analyzed expression level by Western blotting cell lysates for the 
quantity of His6 epitope tag (Figure 3.7C). Expression levels of His6 tagged wild type and 
NMCC Hsp90 is similar. In addition, the SDS mobility of NMCC indicates that it is full 
length and that degradation products do not accumulate. Thus the glycine rich linker 
between the C domains is proteolytically stable in yeast. By comparing the Western 
signal to a standard curve of purified His6 Hsp90 in cell lysate (Figure 3.6), we estimate 
that His6 wild-type Hsp90 accumulates to 130,000 copies per cell and NMCC 
accumulates to 110,000 copies per cell. Assuming an average cell volume of 40 fL (118), 
and excluding nuclear volume (119), we estimate the cytoplasmic concentrations as 
approximately 7 M for NMCC and 8 M for wild-type. Wild-type Hsp90 is 
predominantly dimeric at these concentrations and NMCC is predominantly monomeric.  
Figure 3.6. NMCC protein accumulates to similar levels as wild-type Hsp90 and 
does not prevent growth when wild-type Hsp90 is present. 
(A) Growth of Hsp90ts yeast at permissive temperature is not impeded by the expression 
of NMCC Hsp90. (B) Expression of NMCC in yeast with wild-type Hsp90 does not 
prevent growth. (C) Expression level of NMCC, wild-type, and NMCCcoil in yeast 
determined by quantitative Western blotting. 
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Figure 3.7. NMCC as the sole Hsp90 does not support yeast viability. 
(A) NMCC does not rescue growth of a Hsp90ts strain at 37 °C. (B) NMCC does not 
rescue growth at 23 °C in the absence of other Hsp90 sources. (C) Western blot analysis 
of cell lysates demonstrates that NMCC protein accumulates to similar levels as wild-
type Hsp90.
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Together, these results indicate that monomeric NMCC cannot function as the sole Hsp90 
in vivo.  
 
Activation of v-src and GR in vivo. 
The molecular mechanism by which Hsp90 activates substrates is poorly 
understood. The variable co-chaperone requirements for kinase and hormone receptor 
substrates (46, 60) suggests different mechanisms for each class of substrate. Using 
NMCC, we analyzed the requirement of Hsp90 dimerization for the activation of both a 
kinase (v-src) and a hormone receptor (GR). Both of these substrates can be readily 
analyzed in vivo where the full complement of co-chaperones is present. These 
experiments were done in yeast with a Hsp90ts background such that cells with NMCC 
could be grown to sufficient number, then transferred to non-permissive temperature in 
order to monitor NMCC-dependent substrate activity (Experimental setup illustrated in 
Figure 3.8). 
 
V-src is a promiscuous tyrosine kinase. Yeast have very low background levels of 
phosphotyrosine and expression of v-src causes a dramatic and Hsp90-dependent increase 
in phosphotyrosine (71). When v-src is induced from a galactose inducible promoter in 
the presence of wild-type Hsp90, Western blotting with an anti-phosphotyrosine antibody 
shows that many yeast proteins are phosphorylated by v-src (Figure 3.9A). In contrast, 
when v-src is induced with NMCC Hsp90, the v-src kinase accumulates, but proteins  
Figure 3.8. Experimental setup to analyze client protein activity in Hsp90ts yeast.
Experimental setup to analyze (A) v-src and (B) GR activity in Hsp90ts yeast.
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Figure 3.9. In yeast cells, NMCC does not aid in the activation of v-src or GR. 
(A) Western blots to detect v-src levels and phosphotyrosine levels in yeast with no 
active Hsp90, wt Hsp90, or NMCC Hsp90. In yeast with NMCC and all other Hsp90 
inactive, v-src activity is compromised relative to cells with wild-type Hsp90. (B) 
Quantification of phosphotyrosine and v-src levels. (C) Reporter activity from a GRE 
driven promoter is defective with NMCC compared to wild-type Hsp90.
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with phosphotyrosine do not accumulate indicating that v-src is inactive (Figure 3.9 
A&B). NMCC Hsp90 does not activate v-src in vivo. 
 
In yeast, GR responds to steroid agonists including deoxycorticosterone (DOCS) 
to enhance expression from promoters with glucocorticoid response elements (GRE’s) 
(7). When yeast expressing GR are stimulated with DOCS, wild-type Hsp90 aids in the 
hormone induced expression of -Gal from a GRE containing promoter (Figure 3.9B). In 
contrast, NMCC does not increase reporter expression relative to cells with no active 
Hsp90. NMCC Hsp90 does not activate GR in vivo. 
 
NMCC function is rescued by addition of a coiled-coil dimerization motif. 
The lack of function observed for NMCC Hsp90 could be due to lack of 
dimerization or some other unintended consequence of the engineering strategy. For 
example, function of Hsp90 may require transient dissociation of the C domain and 
NMCC may be non-functional because it slows C domain dissociation. To address these 
concerns, we appended a coiled-coil dimerization domain to generate NMCCcoil (Figure 
3.10A). The coiled-coil should induce this construct to form dimers. If NMCC is 
functionally defective because it is monomeric, then NMCCcoil should rescue both 
dimerization and function. In size exclusion chromatography NMCCcoil has a radius of 
gyration consistent with the dominant solution form being dimeric, with a small amount 
of tetramer also observed (Figure 3.10B).  
Figure 3.10. Dimerization of NMCCcoil rescues in vitro and in vivo function. 
(A) Architecture and putative structural model of NMCCcoil dimer. (B) Size exclusion 
chromatography indicates that appending the coiled-coil domain transforms the parental 
NMCC monomer into a predominantly dimeric NMCCcoil. (C) ATPase activity of 
NMCCcoil is rescued compared to NMCC. (D) As the sole Hsp90 source, NMCCcoil 
supports yeast viability.
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Is NMCCcoil functionally active? It is about 70% as active as wild-type Hsp90 
for ATPase activity in vitro (Figure 3.10C). In addition, NMCCcoil enables yeast growth 
as the sole source of Hsp90 (Figure 3.10D). NMCCcoil expresses to about one third the 
level of wild-type Hsp90 (Figure 3.6). Consistent with previous findings that decreased 
Hsp90 levels result in reduced growth at elevated temperatures (4), yeast with NMCCcoil 
are temperature sensitive (data not shown). Our analysis of NMCCcoil demonstrates that 
the coiled-coil domain rescues dimerization, in vitro ATPase activity, and the ability to 
serve as the sole Hsp90 in yeast. Because coiled-coil induced dimerization rescues 
function in NMCCcoil, we conclude that the parental NMCC construct is defective 
because it is monomeric.  
 
Discussion 
Our results indicate that dimerization of NMCC Hsp90 is required to position the 
catalytic machinery for efficient ATP hydrolysis. The recently determined crystal 
structure of yeast Hsp90 with AMPPNP and Sba1p (10) indicates that ATP binding 
induces a conformational change in the N domain that contributes to NM dimerization 
(10). Specifically, amino acids 94-125 change conformation relative to both the apo and 
ADP structures of the N domain (9) forming a lid over the bound nucleotide. When this 
lid is closed over ATP, hydrophobic interactions (primarily by I96 and F120) are made 
across the interface that favors dimerization. Our results indicate that these cross-subunit 
interactions are required to position the catalytic machinery for efficient ATP hydrolysis. 
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We find that NMCC monomers have an in vitro ATPase activity that is at most 3 
% the level of wild-type Hsp90. This level of ATPase activity is at the extreme low end 
of the spectrum of ATPase activities that have been observed in Hsp90 point mutants that 
support yeast growth (16). Of note, studies on mixtures of full-length and C domain 
constructs show that full-length/C-domain heterodimers have an ATPase activity 
approximately 30 % that of wild-type homodimers (93), well within the range of ATPase 
activity required for in vivo activity. Why does the NMCC monomer have lower in vitro 
ATPase activity compared to full-length/C-domain heterodimers? The ATPase activity 
measured for NMCC monomers was determined at low NMCC concentration where 
monomers dominate. The ATPase activity for full-length/C-domain heterodimers was 
determined by titrating increasing concentration of C-domain and assuming equal 
dimerization probability for all species. This last assumption was based on the 
observation that both full-length and C-domain constructs have similar dimerization 
constants in the absence of nucleotide. Under the conditions of the ATPase assay 
nucleotide promoted dimerization of the NM domains may favor full-length homodimers 
over full-length/C-domain heterodimers. In this case the activity of full-length/C-domain 
heterodimers would be an overestimate. 
 
Human Hsp90 has high sequence conservation with yeast Hsp90 (58 % sequence 
identity), but different ATPase properties (22, 29). The in vitro ATPase activity of human 
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Hsp90 is about 10 % that of yeast. A monomeric NM construct of human Hsp90 is 
reduced in activity by 10-fold relative to the full-length, suggesting that dimerization is 
important for efficient ATP hydrolysis in human Hsp90 as well as in yeast. However, 
human NM constructs do not exhibit concentration dependent ATPase activity at protein 
concentrations up to 100 M. Thus the activity of human NM Hsp90 monomers appears 
to be about 1 % the rate of full-length yeast Hsp90. With the data in this paper we cannot 
accurately determine the level of ATPase activity of yeast NMCC monomers, but find 
that it is less than 3 % of full-length yeast Hsp90 and it may be similar to monomers of 
human Hsp90.  
 
Two possible explanations for the human NM results are that either human Hsp90 
does not require NM dimerization for efficient ATPase hydrolysis, or the dimerization 
constant of NM is weaker in human Hsp90 than in yeast. We note that there are two 
amino acid changes at the NM dimer interface (V23F and L378I – yeast to human) that 
may reduce the affinity of this interface in human Hsp90. Also, human NM constructs 
have greatly reduced ATPase activity compared to full-length, indicating that 
dimerization contributes to efficient ATPase activity. Alternatively, it is possible that 
human NM constructs have reduced activity because of removal of the C domain. The 
monomer design strategy used in this paper could be used to differentiate these 
possibilities by generating human monomers with intact C domains. Lastly, human 
Hsp90 rescues yeast with endogenous Hsp90 knocked out (7), indicating that human 
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Hsp90 functions with yeast co-chaperones and substrates, some of which bind in a 
nucleotide-dependent manner to Hsp90 (22, 91). These lines of reasoning suggest that 
human Hsp90 functions by the same basic mechanism as yeast Hsp90, but that the 
affinity between the NM domains is stronger in yeast. 
 
Changes in Hsp90’s in vitro ATPase activity correlate loosely with in vivo 
function. Point mutations that destroy in vitro ATPase activity are non-functional in yeast 
(11, 96), but mutations that alter ATPase activity from 2 % to 400 % of wild-type levels 
are tolerable under non-stressful conditions (16). The in vivo ATPase activity of Hsp90 
mutants may be buffered through binding to co-chaperones. Hundreds of yeast proteins 
interact with Hsp90 (8), and at least three have been shown to impact the ATPase rate of 
Hsp90 (23, 30, 34). Modulating the level of one of these co-chaperones in human cells 
has been shown to dramatically alter the activity level of an Hsp90 substrate (48). One of 
the unmet challenges in the study of Hsp90 is to understand how ATPase hydrolysis 
contributes to substrate activation.  
 
NMCC will be a useful model for analyzing the binding properties of monomers 
to co-chaperones and substrates and the potential role of monomers in the Hsp90 
conformational cycle. At cytoplasmic concentrations, Hsp90 is predominantly dimeric, 
However, Hsp90 subunits exchange rapidly, on the same time scale as ATP hydrolysis, 
suggesting that monomers of Hsp90 form transiently during the activation of substrates 
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(93). In addition to transient formation of Hsp90 monomers, the equilibrium population 
of monomeric Hsp90 in the cytosol is approximately 1000 copies/cell (based on 
expression level and the observed dimer dissociation constant) compared to 130,000 
copies of Hsp90 dimers. Some substrates or co-chaperones may preferentially interact 
with Hsp90 monomers during part of the Hsp90 chaperone cycle. In addition, the binding 
of Hsp90 to transcription factors and other proteins with nuclear localization signals 
causes Hsp90 to traffic to the nucleus where it can accumulate at low abundance (120). 
The low concentration of Hsp90 in the nucleus should favor dimer dissociation, and 
perhaps Hsp90 monomers have a function in the nucleus. NMCC Hsp90 provides a tool 
to study full-length Hsp90 monomers both in vitro and inside cells. 
 
Conclusions 
We find that the in vitro ATPase activity of NMCC is at best at the extreme low 
end of the range observed to support yeast viability and that NMCC does not support 
yeast viability. These observations indicate that the cellular environment is not sufficient 
to rescue the chaperone function of monomeric Hsp90. In addition, NMCC does not 
increase the activation of v-src nor GR in cells, indicating that Hsp90 dimerization is 
required to chaperone these specific substrates in yeast. 
 
85 
 
 
 
CHAPTER IV 
 
Hsp90 ATPase activity is required for in vivo function 
 
This work was previously published as: 
Natalie Wayne, YuShuan Lai, Les Pullen, and Daniel N. Bolon. (2010) Modular 
Control of Cross-oligomerization: Analysis of Superstabilized Hsp90 Homodimers In 
Vivo. The Journal of Biological Chemistry. 285(1), 234-241. 
 
 Experiments designed to analyze dimer assembly (Figure 4.4A&B) were 
performed by YuShuan Lai. NMCcoil protein for AUC experiments (Figure 4.2B) was 
provided by Les Pullen.  
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Abstract 
Homo-oligomeric proteins fulfill numerous functions in all cells. The ability to 
co-express subunits of these proteins that preferentially self-assemble without cross-
oligomerizing provides for controlled experiments to analyze the function of mutant 
homo-oligomers in vivo. Hsp90 is a dimeric chaperone involved in the maturation of 
many kinases and steroid hormone receptors. We observed that co-expression of different 
Hsp90 subunits in Saccharomyces cerevisiae caused unpredictable synthetic growth 
defects due to cross-dimerization. We engineered super-stabilized Hsp90 dimers that 
resisted cross-dimerization with endogenous Hsp90 and alleviated the synthetic growth 
defect. Super-stabilized Hsp90 dimers supported robust growth of S. cerevisiae indicating 
that dissociation of Hsp90 dimers could be hindered without compromising essential 
function. We utilized super-stabilized dimers to analyze the activity of ATPase mutant 
homodimers in a temperature sensitive yeast background where elevated temperature 
inactivated all other Hsp90 species. We found that ATP binding and hydrolysis by Hsp90 
are both required for the efficient maturation of GR and v-src confirming the critical role 
of ATP hydrolysis in the maturation of steroid hormone receptors and kinases in vivo.  
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Introduction 
The advent of modern genetic technology, including synthetic biology, enables 
many powerful approaches for both medical intervention and scientific exploration. 
Unfortunately, genetic manipulations frequently have unanticipated and hard-to-predict 
biochemical and physiological consequences. The analysis and manipulation of homo-
oligomeric systems is particularly challenging because co-expression often leads to cross-
oligomers with unanticipated activity (121). The ability to control cross-oligomerization 
is important for the investigation of numerous essential oligomeric proteins in vivo. Here, 
we present a general and modular approach to restrict cross-oligomerization and apply it 
to examine the role of ATP hydrolysis in the essential Hsp90 chaperone in vivo. 
 
Hsp90 forms a thermodynamically stable dimer (122) that has a dissociation 
constant of about 60 nM (93) well below the estimated concentration of Hsp90 (about 15 
M) in S. cerevisiae cells (5). Of note, Hsp90 subunits undergo subunit exchange with a 
half-life of less than a minute (93), while Hsp90 hydrolyzes ATP with a turnover rate of 
about 1 min-1 (93). Because subunit exchange requires dimer dissociation, these results 
indicate that Hsp90 monomers can form during the Hsp90 ATPase cycle. 
 
In vitro studies have identified point mutations in Hsp90 that disrupt ATP binding 
and/or hydrolysis. In the N-domain, the D79N point mutation disrupts hydrogen bonding 
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with the adenine base and prevents nucleotide binding (11). While Hsp90 does not 
contain signature Walker motifs, it does contain catalytic groups common to many 
ATPases including glutamate 33 that is positioned to activate a water molecule for 
nucleophilic attack on the scissile phosphodiester bond (11). The E33A point-mutation 
results in Hsp90 competent to bind but not hydrolyze ATP. Both the E33A ATP 
hydrolysis mutant and the D79N ATP binding mutant fail to support yeast viability 
demonstrating the critical role of ATP hydrolysis by Hsp90 in vivo (11, 96). 
 
The function of Hsp90 is tied into many different biochemical pathways. Roughly 
ten percent of the yeast proteome binds to Hsp90 (8) emphasizing the importance of 
studying Hsp90 in its cellular environment where all binding partners are present. Many 
of these Hsp90 binding partners are co-chaperones required for the maturation of clients 
(8, 45, 123, 124). 
 
Investigating ATPase deficient Hsp90 mutants in vivo has been challenging for 
two reasons: (1) ATPase mutants are inviable and (2) co-expression of different Hsp90 
variants leads to cross-dimerization. Temperature sensitive (ts) Hsp90 mutants (107) 
provide a potential means to grow cells co-expressing ATPase mutants that can then be 
studied at elevated temperatures where Hsp90ts is inactivated. However, co-expression of 
different Hsp90 subunits leads to the formation of cross-dimers whose biochemical 
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activity is unpredictable. To overcome this challenge, we developed a strategy to thwart 
cross-dimerization. Using this system combined with inducible client expression systems, 
we investigated the maturation of clients in yeast where the only potential Hsp90 activity 
was from ATPase-deficient homodimers. 
 
Results 
Cross-dimers of Hsp90 have unpredictable functions.  
Co-expression of ts NMCG170D (NMC refers to full-length Hsp90 containing the 
N, M, and C domains) in iG170D cells with the ATP-binding deficient NMCD79N caused 
a synthetic growth defect in yeast (Figure 4.1A). In contrast, healthy growth was 
observed when the same NMCD79N construct was introduced into W303 yeast with wild-
type NMC. The G170D and D79N mutations are unlikely to affect dimer association as 
they are both located in the N-domain that is physically distant from the constitutive 
dimer interface in the C-domain (10). In the co-expression strains, dimers should 
equilibrate to form a distribution of three possible dimer species (Figure 4.1A). The 
synthetic growth defect from co-expression of G170D and D79N point mutants could be 
caused by G170D/D79N cross-dimers. 
 
 
Figure 4.1. Co-expression of different NMC Hsp90 variants in vivo leads to the 
formation of cross-dimers with unpredictable function. 
(A) Growth of yeast expressing different NMC variants: temperature sensitive G170D 
alone (top left), G170D with the ATP-binding deficient D79N point mutant (top right), 
wild-type Hsp90 alone (bottom left), wild-type with D79N (bottom right). Expression of 
NMCD79N caused an unanticipated growth defect when expressed with NMCG170D. 
Dimer exchange model illustrated on the right shows the probable NMC dimers species 
present in the co-expression cells. (B) Strategy to hinder cross-dimerization. Appending 
a coiled-coil dimerization domain super-stabilizes NMCcoil homodimer species and 
shifts the dimer exchange equilibrium to disfavor NMCcoil/NMC cross-dimers.   
90
Figure 4.1
G170D G170D +
D79N
G170D/D79ND79N2
Probable Hsp90 dimers:
(A)
2+
G170D2
WT2 D79N2 WT/D79N
WT
WT
+ D79N
(B)
+ 2
91
92 
 
 
 
Super-stabilization strategy to hinder cross-dimerization.  
Cross-dimerization is governed by a subunit exchange reaction where the free 
energy of association for each dimer species dictates the equilibrium distribution (125). 
The difference in free energy of dimerization between the heterodimer and the average of 
both homodimers controls the equilibirium population of all species. To disfavor cross-
dimerization, we fused NMC to an additional dimerization domain consisting of a 33 
amino-acid coiled-coil peptide (see methods in Chapter II for sequence) to create super-
stabilized Hsp90 dimers that we refer to as NMCcoil (Figure 4.1B). In theory, the super-
stabilization of one homodimer is sufficient to shift the equilibrium away from cross-
dimers. 
 
The coiled-coil super-stabilizes Hsp90 dimers. 
Because dimerization and folding of the C-domain are coupled (126), dimer 
strength can be determined from unfolding studies of this domain. We compared the 
thermodynamic unfolding stability of the isolated C-domain to a construct with the 
coiled-coil that we refer to as Ccoil (C-domain plus coiled-coil). Addition of the coiled-
coil enables it to remain folded at concentrations of urea where the isolated C-domain 
itself unfolds (Figure 4.2A). Fits of the denaturation curves indicate that the coiled-coil 
increases stability by 12 kJ/mol/M subunit. In a dimer exchange model, this energetic  
Figure 4.2. Superstabilization strategy is compatible with Hsp90 function. 
(A) Appending a coiled-coil super-stabilizes the C-domain of Hsp90 as determined by 
urea denaturation monitored by circular dichroism. (B) Full-length NMCcoil behaves as 
a dimer during analytical ultracentrifugation. Single species fit indicates that the 
molecular weight is 181 kD (similar to the theoretical MW of a dimer: 172 kD). (C) 
NMCcoil is compatible with efficient ATP hydrolysis. ATP hydrolysis can be blocked 
with the Hsp90-specific inhibitor geldanamycin (GA). (D) NMCcoil supports yeast 
viability as the sole Hsp90 and expressed to similar levels as NMC based on Western 
blotting of yeast lysates. Both NMC and NMCcoil samples were analyzed on the same 
SDS PAGE gel and blot and intervening lanes were removed for presentation clarity.
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difference reduces cross-dimer accumulation to less than 1 % of the total population 
when each subunit is at equal abundance.  
 
The coiled-coil is compatible with Hsp90 function. 
To avoid perturbing Hsp90 function, we chose a small coiled-coil dimerization 
domain and inserted it into the disordered C-terminal tail of Hsp90. Having multiple 
dimerization domains in one polypeptide raises the possibility for higher order 
aggregation. However, analytical ultracentrifugation (Figure 4.2B) confirms that 
NMCcoil is dimeric at physiological concentration. In addition, higher order oligomers 
are not observed even at 20-fold higher concentration in size exclusion chromatography 
(Figure 4.3). 
 
The slow rate of ATP hydrolysis by NMC (about 1 min-1) occurs on the same 
time scale as subunit exchange (93), raising the possibility that strengthened dimerization 
may impair ATPase activity. However, we find that NMCcoil hydrolyzes ATP at a rate 
similar to wild-type NMC lacking the coiled-coil (Figure 4.2C). We confirm that the 
observed ATPase activity is from Hsp90 by using the Hsp90-specific inhibitor GA. 
Because Hsp90 interacts with multiple co-chaperones and clients that may be impacted 
by the coiled-coil inside cells, we next tested the function of super-stabilized NMCcoil 
dimers to support yeast viability. NMCcoil was introduced into yeast whose only other  
Figure 4.3. Superstabilized NMCcoil is dimeric.
Superstabilized NMCcoil has a similar elution profile to wild-type Hsp90 on a Sepha-
dex 200 size exclusion column indicating that both molecules assume extended dimeric 
conformations. Protein samples were injected at about 250 µM. The theoretical molecu-
lar weight of dimers are 164 kD (wt) and 172 kD (NMCcoil). 
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copy of Hsp90 was encoded on a URA3 marked plasmid subject to negative selection 
using 5-FOA. We find that NMCcoil supports healthy yeast growth as the sole Hsp90 
when 5-FOA was utilized to select for loss of the URA3 marked plasmid (Figure 4.2D). 
In addition, NMCcoil expresses to similar steady state levels as NMC (Figure 4.2D). 
From these results we conclude that the coiled-coil is compatible with Hsp90 function. 
 
Super-stabilization leads to preferential homodimer assembly. 
To experimentally analyze dimer assembly, we took advantage of the observation 
that NMC and truncated C-domain form cross-dimers with distinct ATPase activity (93, 
126). Increasing C-domain concentration caused a marked decrease in ATPase activity 
from NMC (Figure 4.4A). In contrast, the strengthened self-association of NMCcoil 
prevented cross-dimerization with C-domain and resulted in NMCcoil ATPase activity 
that was refractory to inhibition by C-domain. In principle, the observed lack of ATPase 
inhibition of NMCcoil by the C-domain could also be caused by either slow kinetics of 
subunit exchange (and failure to reach equilibrium dimer distributions), or NMCcoil/C-
domain heterodimers having robust ATPase activity. In either of these cases, mixtures of 
NMCcoil and Ccoil would exhibit uninhibited ATPase levels. We find that mixtures of 
NMCcoil and Ccoil display essentially the same equilibrium ATPase inhibition response 
as NMC and C mixtures (Figure 4.4B). Thus, NMCcoil dimer exchange equilibrates in 
the experiment and NMCcoil ATPase activity can be reduced through cross-dimerizing  
Figure 4.4. Superstabilization disfavors cross-dimerization. 
(A) NMCcoil Hsp90 is refractory to cross-dimerization with C-domain subunits lack-
ing the coiled-coil domain. (B) Similarly, superstabilized Ccoil prevents cross-
dimerization with NMC subunits lacking the coiled-coil. (C) Hindering cross-
dimerization enabled the co-expression of NMCcoilD79N with NMCG170D without 
severe growth defects. Growth of yeast expressing the temperature sensitive 
Hsp90G170D alone (left), or in combination with NMCcoilD79N (right).
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with a truncated Ccoil. We conclude that NMCcoil dimers are refractory to cross-
dimerization with Hsp90 subunits lacking the coiled-coil.  
 
 As observed previously, full-length/C-domain heterodimers have residual ATPase 
activity (93) which contradicts our finding in Chapter III that Hsp90 monomers have at 
most 3 % of wild-type ATPase activity (Figure 3.4).  When titrating increasing 
concentrations of C-domain, we are assuming equal dimerization probability for all 
species based on the observation that full-length and C-domain constructs have similar 
dimerization constants in the absence of nucleotide. In the ATPase assay, nucleotide 
promoted dimerization of the NM domains may favor full-length homodimers making the 
ATPase activity of full-length/C-domain heterodimers an overestimate.  
 
NMCcoil
D79N 
rescues growth when co-expressed with ts NMC
G170D
.  
If the synthetic growth defect of cells co-expressing G170D and D79N point-
mutants was caused by cross-dimerization, then preventing cross-dimerization should 
enable healthy growth of cells expressing both Hsp90 variants. Indeed, we observed that 
co-expressing NMCG170D and NMCcoilD79N resulted in healthy growth (Figure 4.4C). 
This yeast strain is virtually identical to the strain in Figure 4.1A (top), with the exception 
that cross-dimers are suppressed. The phenotypic effect of this small change 
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demonstrates the sensitive nature of the complex Hsp90 interactome in vivo and 
underscores the importance of robust regulation of cross-dimers. 
 
ATPase-deficient Hsp90 mutants function at elevated temperature. 
The yeast system that we developed to study ATPase deficient Hsp90 mutants in 
vivo requires the inactivation of ts NMCG170D at elevated temperature; therefore, we first 
sought to ensure that the ATPase mutants are refractory to heat inactivation at the 
required temperature of these experiments (37 °C). Temperature scans of both E33A and 
D79N ATPase-deficient mutants and wild-type NMC, monitored by circular dichroism 
reproducibly show a small-amplitude transition at about 55 ºC (Figure 4.5A). However, 
because of the small amplitude of this change, we sought a more robust metric of 
temperature induced Hsp90 mis-folding. Higher order aggregation was the most 
pronounced physical affect that we observed for mis-folded Hsp90. Using native PAGE, 
we observed temperature-dependent formation of higher order aggregates for wild-type 
Hsp90 (Figure 4.5B) that occured at the same transition temperature observed by CD. 
Using the native gel approach, we find that both of the ATPase mutants are natively 
structured at 37 °C (Figure 4.5C). Next, we analyzed the ability of the ATPase mutants to 
serve as anti-aggregation chaperones, an ATP-independent function of wild-type Hsp90 
(88, 90). We performed light-scattering experiments to analyze aggregation of the hard-
to-fold CFTR-NBD1. As previously observed (88), NBD1 aggregation at elevated 
temperatures can be reduced in vitro by Hsp90 in the absence of ATP (Figure 4.5D).  
Figure 4.5. Hsp90 ATPase mutants are stable at 37 ºC. 
(A) The E33A ATP hydrolysis and  D79N ATP binding point mutants as well as 
wild-type NMC all maintain native secondary structure content as judged by circular 
dichroism at temperatures up to 50 °C. Data plotted as a change in ellipticity with a 
+1 offset between samples. (B) Higher order aggregates of wild-type NMC are 
detectable at temperatures above 55 °C by Coomassie-stained Native PAGE. (C) At 
37 °C both point mutants are natively folded as judged by Native PAGE. (D) The 
ATPase mutants function at 37 °C to rescue aggregation of the hard-to-fold CFTR 
NBD1 domain in vitro (an ATP independent function of Hsp90) as assessed by light 
scattering of aggregated particles.
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Both E33A and D79N NMC are capable of suppressing NBD1 aggregation at 37 ºC 
(Figure 4.5D). From these results, we conclude that the ATPase mutants of Hsp90 are 
stable at 37 ºC. 
 
Maturation of v-src.  
Co-expression of ts NMCG170D with ATPase-deficient NMCcoil mutants enabled 
healthy growth at permissive temperature providing a large reservoir of cells that could 
be heat inactivated prior to inducing the expression of a client (Figure 4.6 A). When v-src 
expression was induced at elevated temperature in ts NMCG170D yeast, v-src accumulated 
at relatively low levels and failed to phosphorylate the tyrosines of endogenous yeast 
proteins (Figure 4.6B). Because yeast have extremely low amounts of endogenous 
tyrosine kinases, background phosphotyrosine levels were minute. Importantly, both v-
src accumulation and kinase function could be rescued by co-expression with wild-type 
NMC or NMCcoil indicating that the super-stabilizing coiled-coil is compatible with 
efficient v-src maturation. The E33A and D79N ATPase-deficient NMCcoil mutants both 
resulted in decreased v-src accumulation and background levels of phosphotyrosine. 
Accumulation of SspB, a non-Hsp90 dependent protein, is not dramatically impacted by 
the ATPase mutants indicating that general aspects of transcriptional activation (127) are 
functional in these cells (Figure 4.6C).  
 
 
Figure 4.6. ATPase deficient NMCcoil variants are unable to mature v-src kinase in 
yeast. 
(A) Experimental setup to analyze ATPase deficient Hsp90 mutants in yeast. (B) In 
yeast, NMCcoil mutations that disrupt ATP binding (D79N) or hydrolysis (E33A) both 
lead to reduced v-src accumulation and background levels of tyrosine kinase activity. 
(C) Induction of general protein expression is only modestly impacted by the NMCcoil 
ATPase mutants as evidenced by the accumulation of a non-Hsp90 client, the SspB 
protein from E. coli.
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Glucocorticoid receptor (GR) activation.  
GR transcriptional activation in response to the hormone activator 
deoxycorticosterone (DOCS) was monitored using a -galactosidase reporter (7). Yeast 
harboring wild-type NMC showed a robust increase in hormone-stimulated reporter 
activity compared to yeast whose sole source of Hsp90 was heat inactivated (Figure 
4.7A). We observed similar hormone stimulated GR activity with both wild-type NMC 
and NMCcoil indicating that the coiled-coil fusion is compatible with efficient hormone 
receptor activation. Both the ATP binding mutant (D79N) and the ATP hydrolysis mutant 
(E33A) NMCcoil variants showed markedly reduced GR activity indicating that both 
ATP binding and hydrolysis by Hsp90 are important for efficient hormone receptor 
activation. The accumulation of GR was impacted by the ATPase mutants with E33A and 
D79N resulting in increased accumulation of GR (Figure 4.7B). 
 
Hsp90 dimers constitute the essential biological oligomer.  
Hsp90 dimers transiently dissociate to monomers on the same time scale as ATP 
hydrolysis (93) leading to the possibility that both monomers and dimers are part of the 
chaperone cycle. In contrast to the rapid dimer exchange of wild-type subunits, we 
observed that super-stabilized NMCcoil dimers have a half-life of eight hours to 
equilibrate (Figure 4.8A). NMC dimers equilibrate with a half-life of about 30 seconds 
(Figure 4.9). These results indicate that dimer dissociation is the rate limiting step in the  
Figure 4.7. Hsp90 ATPase mutants do not mature GR in yeast. 
(A) Glucocorticoid receptor activation monitored in yeast. Yeast with the temperature 
sensitive NMCG170D as well as ATPase deficient NMCcoil variants were heated to 
inactivate NMCG170D prior to stimulation with saturating levels of DOCS (10 µM). 
Neither D79N nor E33A NMCcoil resulted in reporter activity levels significantly 
greater than background using a single-tailed student T-test.  Error bars represent SEM. 
(B) Expression level of GR analyzed by Western blots of yeast lysates.
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Figure 4.8. Dimers of Hsp90 constitute the essential biological oligomer whose 
ATPase function is required for maturation of clients. 
(A) NMCcoil reduces the rate of subunit exchange to time-scales that are irrelevant to 
the biochemical function of Hsp90 in vivo. Truncated and full-length protein were 
mixed and allowed to exchange subunits prior to assessing the amount of full-
length/full-length dimers by monitoring specific ATPase activity. (B) Model of the 
ATPase dependent function of Hsp90 dimers in vivo. ATP hydrolysis by Hsp90 dimers 
leads to the maturation of clients.
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Figure 4.9. Subunit exchange of Hsp90 dimers.
(A) Wild-type Hsp90 exchanges dimer subunits rapidly. Addition of excess truncated 
C-domain leads to the rapid formation of full-length/C-domain heterodimers. (B) 
Addition of a coiled-coil dimerization domain to the C terminus of Hsp90 stabilizes the 
dimer state and slows dimer exchange.  
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dimer exchange reaction and that NMCcoil Hsp90 dimers dissociate on a time scale that 
is too slow to be relevant for cellular processes such as signal transduction. Our 
observation that NMCcoil hydrolyzes ATP at a similar rate to NMC indicates that 
dissociation of yeast Hsp90 subunits is not required for ATP hydrolysis in vitro. In 
addition, our observations that NMCcoil Hsp90 function is indistinguishable from wild-
type Hsp90 in vivo indicate that Hsp90 dimers are capable of providing all essential 
functions (Figure 4.8B). 
 
Discussion 
The ability of NMCcoil to efficiently chaperone clients and support viability 
shows that super-stabilized Hsp90 dimers are functional in vivo. The strength of 
NMCcoil subunit association in vivo may be influenced by interactions with co-
chaperones. However, the 1000-fold reduced rate of subunit exchange observed in vitro 
for NMCcoil (Figure 4.8A) makes it probable that subunit association is also 
strengthened in vivo. In addition, appending the coiled-coil to D79N rescues robust 
growth of yeast with the temperature sensitive G170D (Figure 4.4C) consistent with the 
coiled-coil strengthening dimerization and preventing subunit mixing in vivo. Together 
these results indicate that strengthened subunit association is compatible with Hsp90 
function. 
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C-domain dimerization is critical for Hsp90 function. We have observed that 
strengthened Hsp90 dimerization is compatible with function and previously reported that 
preventing association of Hsp90 subunits abrogates chaperone function (126). Of note, 
the C-domain dimer interface is composed of a large patch of hydrophobic amino acids 
rich in Ile, Val, and Leu (Figure 4.10). Protein folding studies indicate that clusters of 
these three aliphatic amino acids form strong associations capable of directing folding 
pathways (128, 129). The aliphatic patch at the C-domain dimer interface is consistent 
with the critical role of subunit association in the function of the Hsp90 and our 
observations that subunit dissociation does not appear to be required for essential Hsp90 
function. 
 
The value of preventing cross-dimerization in co-expression studies is 
dramatically illustrated by the growth defect caused by co-expression of NMCD79N and 
NMCG170D. This growth defect is clearly mediated by the formation of NMCD79N/G170D 
heterodimers as healthy growth is restored when cross-dimerization is abrogated using 
NMCcoilD79N homodimers. The growth defect caused by NMCD79N/G170D heterodimers 
could formally be due to either depletion of NMCG170D homodimers or by toxicity of the 
NMCD79N/G170D heterodimers. In either case, using NMCcoil ATPase mutant homodimers 
to prevent cross-dimerization enabled direct analysis of the activity of both E33A and 
D79N ATPase mutants without contributions from cross-dimer species. 
 
Figure 4.10. Molecular image of the C-domain dimer interface of Hsp90. 
Molecular image highlighting the cluster of ILV (Ile, Val and Leu) positions. The 
C-domain is shown in cartoon form from position 540-680 of the PDB file 2CG9 and 
the ILV amino acids are shown as spheres (amino acids V639, L642, L645, L646, 
I668, L671, I672, L674, and L676) .
117
Figure 4.10
118
119 
 
 
 
Our experiments clearly demonstrate that ATP binding and hydrolysis by Hsp90 
are required for the maturation of both v-src and GR in S. cerevisiae. Mutations that 
abrogate the hydrolytic-activating glutamate (E33A) or binding to the adenine ring 
(D79N) both resulted in null levels of v-src and GR activity in vivo. These findings 
provide important confirmation that the ATPase based models proposed for Hsp90 
activity in vitro (9, 17, 18, 130) extend to Hsp90 function in vivo. The mechanistic details 
of Hsp90 ATPase activity have been well-examined in its purified form (22, 93, 124); 
however, until now it has not been possible to extend these analyses monitoring client 
activation in vivo. Our findings that E33A and D79N NMCcoil fail to mature GR in vivo 
are consistent with previous observations that analogous mutations prevent Hsp90 from 
stimulating the binding of progesterone receptor to its hormone ligand in vitro (66). Many 
studies demonstrate that Hsp90’s primary role in stimulating hormone receptors is 
opening of the receptor to enable access of hormone to the otherwise sequestered binding 
site (131). Our results indicate that in vivo this process requires both ATP binding and 
hydrolysis. 
 
We have presented a modular strategy to control cross-oligomerization and 
utilized it to analyze ATPase mutants of Hsp90 in a temperature sensitive yeast 
background. These studies confirm the critical role of ATP binding and hydrolysis by 
Hsp90 in the maturation of kinases and steroid hormone receptors in vivo. The super-
stabilized Hsp90 tools that we developed provide a foundation to explore other non-
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viable Hsp90 mutants in vivo and to extend our analysis to other clients. Because our 
super-stabilization strategy is based on coiled-coil peptides whose characteristics are 
extremely modular, it is directly applicable to many homodimeric systems. In addition, 
the existence of -helical peptides that specifically self-assemble with different orders 
including dimers, trimers, tetramers, and pentamers (132, 133) make the approach 
described here widely applicable to the investigation of homo-oligomeric systems. 
 
From the engineering of a monomeric Hsp90 variant, it is clear that dimerization 
of Hsp90 is critical for efficient ATP hydrolysis as well as the activation of a kinase and a 
steroid hormone receptor client (126). How each subunit in the Hsp90 dimer binds to and 
hydrolyzes ATP during the maturation of a client remains unclear. 
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CHAPTER V 
 
Charge-rich regions modulate the anti-aggregation  
activity of Hsp90 
 
This work was previously published as: 
Natalie Wayne and Daniel N. Bolon. (2010) Charge-Rich Regions Modulate the Anti-
Aggregation Activity of Hsp90. Journal of Molecular Biology. 401(5):931-9. 
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Abstract 
Protein aggregation can have dramatic effects on cellular function and plays a 
causative role in many human diseases. In all cells, molecular chaperones bind to 
aggregation-prone proteins and hinder aggregation. The ability of a protein to resist 
aggregation and remain soluble in aqueous solution is linked to the physical properties of 
the protein. Numerous physical studies demonstrate that charged atoms favor solubility. 
We note that many molecular chaperones possess a substantial negative charge that may 
allow them to impart solubility on aggregation-prone proteins. Hsp90 is one such 
negatively charged molecular chaperone. The charge on Hsp90 is largely concentrated in 
two highly acidic regions. To investigate the relationship between chaperone charge and 
protein solubility, these charge-rich regions were deleted and the resulting Hsp90 
constructs analyzed for anti-aggregation activity. We found that deletion of both charge-
rich regions dramatically impaired Hsp90 anti-aggregation activity. The anti-aggregation 
role of the deleted charge-rich regions could be due to net charge or sequence-specific 
features. To distinguish these possibilities, we attached an acid-rich region with a distinct 
amino acid sequence to our double-deleted Hsp90 construct. This charge-rescue construct 
displayed effective anti-aggregation activity indicating that the net charge of Hsp90 
contributes to its anti-aggregation activity. 
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Introduction 
The propensity of a protein to aggregate is linked to the physical properties of the 
protein. Understanding these physical properties has important implications for many 
biological processes that involve protein aggregation including numerous human diseases 
(134-139). The propensity of a protein to aggregate is governed by the energetic and 
kinetic balance between interactions of the protein with solvent versus self-association. 
Both of these interactions must be considered in order to understand the process of 
protein aggregation. 
 
The strength of protein self-association is dramatically influenced by hydrophobic 
contacts (140). By chemical definition, hydrophobic groups prefer to associate with other 
hydrophobic groups relative to aqueous solvent. In order to remain soluble, most 
natively-folded cytoplasmic proteins sequester hydrophobic side-chains from solvent in 
the core of the protein. These hydrophobic side-chains become increasingly exposed to 
solvent when proteins transiently sample mis-folded conformations. For this reason, mis-
folded conformations frequently aggregate in an energetic effort to bury exposed 
hydrophobic surfaces (141).  
 
In contrast to hydrophobic effects, charged amino acids have been shown to 
increase protein solubility. It is well appreciated in biochemistry that proteins are usually 
least soluble at a pH where their net charge is zero (142). From a chemical perspective, 
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charged groups interact favorably with aqueous solvent and are unlikely to self-associate. 
Coulombic repulsive forces between like-charges also influence self-association. 
Experimentally increasing the net charge of aggregation-prone proteins, and increasing 
Coulombic self-repulsion, has been shown to improve protein solubility (97, 143).  
 
Because aggregation is a concentration-dependent event, the aggregation of mis-
folded proteins is enhanced by the crowded environment of the cell (136, 141, 144, 145). 
In cells, many aggregation-prone proteins rely on interactions with molecular chaperones 
(136, 137, 141, 144-146). Molecular chaperones hinder protein aggregation and facilitate 
folding and assembly of proteins into higher order structures (146-148). Many molecular 
chaperones bind to mis-folded proteins and reduce aggregation by shielding hydrophobic 
side-chains from bulk solvent (141). For example, the GroEL (Hsp60) chaperone forms a 
closed barrel around mis-folded proteins, effectively shielding the entire protein from 
bulk solvent (149, 150).  
 
Other chaperones, including Hsp90 and Hsp70, have smaller hydrophobic patches 
capable of binding to mis-folded proteins and partially shielding exposed hydrophobic 
side-chains from solvent (151, 152). Because these systems do not form closed barrels, 
they cannot completely shield mis-folded proteins from solvent exposure. The solubility 
of this type of complex may benefit from additional pro-solubility mechanisms. A high 
net charge on the chaperone complex is one physical property that may improve 
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solubility. The net charge on a chaperone complex has the potential to influence 
solubility through direct solvent interactions and Coulombic self-repulsion. 
 
Results 
Negative charge is a common feature of molecular chaperones. 
We observed that three chaperones with anti-aggregation activity (Hsp90, Hsp70, 
and Hsp33) are characterized by a high negative charge that is evolutionarily conserved 
(Tables 5.1 and 5.2). These three highly charged chaperones all have hydrophobic 
patches that are could partially shield mis-folded proteins from solvent (151-153). In 
addition, the Hsp60 chaperone completely encloses mis-folded proteins (149) and is not 
highly charged. For comparison, the non-chaperone protein triosphosphate isomerase is 
also not highly charged. These observations suggest that the conservation of negative 
charge we observed for Hsp90, Hsp70, and Hsp33 may be due to shared mechanisms of 
anti-aggregation activity. 
 
Hsp90 was one of the most highly charged chaperones we analyzed. It is known 
to suppress the in vitro aggregation of numerous proteins including citrate synthase, 
amyloid beta, p53, and the nucleotide binding domain of the cystic fibrosis 
transmembrane conductance regulator (CFTR-NBD1) (85-88). The ability of Hsp90 to 
suppress protein aggregation in vitro often does not require ATP (88-90). Hsp90 is an 
abundant protein under physiological conditions and its level increases in response to cell  
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Table 5.1. Charge conservation of select cytoplasmic proteins 
 
 Molecular Average charge per 100 
 Chaperone amino acids (±SD; n=6
a
) 
 
 Hsp90 -5.0 ± 0.4 
 Hsp70 -2.5 ± 0.9 
 Hsp33 -5.6 ± 2.0 
 Hsp60 -1.1 ± 0.4 
 Triosephosphate Isomerase
b
 -0.7 ± 0.5 
 
a
Net charge of each chaperone was averaged for six species (Table 5.2). 
b
Non-chaperone cytoplasmic protein analyzed for comparison. 
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Table 5.2. Protein charge analysis of select cytoplasmic proteins 
Species  GenBank accession  net number of  charge per 100 
  number   charge
a
 amino acids amino acids 
Hsp90 
Homo sapiens NP 005339 -39.2 731 -5.4 
Mus musculus NP 034610 -40.2 733 -5.5 
Drosophila melanogaster NP 523899 -35.5 717 -5.0 
Caenorhabditis elegans Q18688  -31.8 702 -4.5 
Saccharomyces cerevisiae CAA97961 -37.3 709 -5.3 
Arabidopsis thaliana CAA68885 -31.8 704 -4.5 
Hsp70 
Homo sapiens EAX03528 -10.1 641 -1.6 
Mus musculus AAC84169 -10.0 641 -1.6 
Drosophila melanogaster NP 524798 -11.6 642 -1.8  
Caenorhabditis elegans P27420 -26.1 661 -4.0 
Saccharomyces cerevisiae AAC04952 -20.3 642 -3.2 
Arabidopsis thaliana CAA05547 -18.1 650 -2.8 
Hsp33 
Synechococcus elongatus BAD79153 -14.5 297 -4.9 
Gloeobacter violaceus Q7NIA2 -11.5 306 -3.8 
Lactobacillus plantarum AAU05733 -15.1 295 -5.1 
Streptococcus pneumoniae P64403 -15.6 290 -5.4 
Bacillus subtilis 1VZY A -12.6 291 -4.3 
Escherichia coli AP 004389 -29.1 292 -10.0 
Hsp60 
Homo sapiens AAA36022 -4.7 573 -0.8  
Mus musculus NP 034607 -3.5 573 -0.6 
Drosophila melanogaster NP 511115 -6.9 573 -1.2 
Caenorhabditis elegans NP 497429 -7.9 568 -1.4 
Saccharomyces cerevisiae CAY81488 -10.8 572 -1.9 
Arabidopsis thaliana CAA77646 -4.0 577 -0.7 
Trisosephosphate Isomerase 
Homo sapiens CAA49379 -0.7 249 -0.3 
Mus musculus CAA37420 0.3 249 0.1 
Drosophila melanogaster CAA40804 -1.8 247 -0.7 
Caenorhabditis elegans NP 496563 -1.5 247 -0.6 
Saccharomyces cerevisiae EDN60396 -2.8 248 -1.1 
Arabidopsis thaliana AAF70259 -4.0 254 -1.6 
a
Predicted net charge at pH 7, determined with the program SEDNTERP. 
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stress where the probability of protein mis-folding and aggregation is increased (5, 154). 
Hsp90 can act as a holder chaperone, protecting mis-folded proteins from unfolding 
further and maintaining them in a folding-competent state (90, 155).  
 
The negative charge of Hsp90 is largely localized in two regions of the protein 
(Figure 5.1A). The acid-rich charged linker (CL) is located between the structured N-
terminal and middle domains of Hsp90. The other acidic region is located at the C-
terminus and is referred to here as the C-terminal extension (CX). Both of these regions 
are believed to be unstructured based on amino-acid composition and were deleted in the 
full-length crystal structure of Hsp90 (10). 
 
Both highly charged regions of Hsp90 can be individually deleted without 
compromising essential chaperone function (94). Flexible regions at the ends of the acid-
rich CL are required for essential chaperone function (156) and were retained in all 
constructs reported here. Hsp90, like many other chaperones, (150, 152) is believed to 
utilize hydrophobic surfaces to bind to exposed hydrophobic regions of mis-folded 
proteins (151).  The acid-rich CL and CX (Figure 5.1A) are among the least hydrophobic 
regions of Hsp90 (Figure 5.2) (157). Thus, deletion of the CL and CX is unlikely to 
interfere with Hsp90 binding to mis-folded proteins. These dispensable charge-rich 
regions provide a convenient system to investigate the role of charge in Hsp90 anti-
aggregation activity. 
Figure 5.1. Hsp90 constructs to test the role of charge-rich regions in anti-
aggregation activity.
(A) Schematic representation of Saccharomyces cerevisiae Hsp90. Hsp90 is composed 
of an N-terminal domain (N), charged-linker (CL), middle domain (M), C-terminal 
domain (C), and C-terminal extension (CX). The charge of Hsp90 is highly concen-
trated in the acid-rich CL and CX regions. (B) To test the role of these charge-rich 
regions in Hsp90 anti-aggregation activity, we made Hsp90 deletion constructs with 
reduced net charge.
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Figure 5.2. Hydrophobicity Plot for Hsp90. 
Hydrophobicity of individual Hsp90 residues determined based on the Kyte-Doolittle 
scale using the ExPASy proteomics server from the Swiss Institute of Bioinformatic 
(157).
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The charge-rich regions of Hsp90 influence anti-aggregation activity. 
To test the role of charge in Hsp90 anti-aggregation activity, we generated 
constructs where the CL, the CX, or both were deleted. Hsp90 has previously been shown 
to reduce the aggregation of CFTR-NBD1, which is highly prone to aggregation at 
elevated temperatures (Figure 5.3) (88, 158). Hsp90 constructs lacking either the charged 
linker ( CL) or the C-terminal extension ( CX) maintained near wild-type anti-
aggregation activity (Figure 5.4A), consistent with previous observations that deleting the 
charged linker from the N-domain resulted in only a modest impact on insulin 
aggregation (159). However, the Hsp90 construct lacking both the charged linker and the 
C-terminal extension ( CL CX) was inefficient at suppressing CFTR-NBD1 
aggregation.  
 
Deletion of the CL and CX reduces the net charge of Hsp90 and may therefore 
have unfavorable effects on the solubility of the chaperone. To test this possibility, we 
measured the propensity of our Hsp90 constructs to aggregate at elevated temperature in 
the absence of CFTR-NBD1. We found that deletion of the CL and the CX of Hsp90 
does not impair the solubility of the chaperone under conditions where CFTR-NBD1 
aggregates (Figure 5.4A right panel, Figure 5.5). These results indicate that the charge-
rich regions of Hsp90 are important for suppressing CFTR-NBD1 aggregation, but not 
for the solubility of Hsp90. 
 
Figure 5.3. Suppression of CFTR-NBD1 and CS aggregation by Hsp90.
The ability of Hsp90 to suppress CFTR-NBD1 (A) and CS (B) aggregation was 
measured with different concentrations of Hsp90. Of note, we find that different 
preparations of CFTR-NBD1 vary in the amount of aggregation that can be 
suppressed by Hsp90. However, for a given preparation, we find that aggregation 
suppression is very reproducible.
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Figure 5.4. Charge-rich regions influence the anti-aggregation activity of Hsp90.
(A) The combined deletion of both the CL and CX impaired the ability of Hsp90 to 
suppress CFTR-NBD1 aggregation at elevated temperature measured by right angle 
light scattering (left panel). In the absence of CFTR-NBD1, all Hsp90 constructs 
maintained wild-type solubility at 45 °C (right panel). (B) The combined deletion of 
both the CL and CX also impaired the ability of Hsp90 to suppress CS aggregation at 
elevated temperature measured by right angle light scattering (left panel). In the 
absence of CS, all Hsp90 constructs maintained wild-type solubility at 43 °C (right 
panel).
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Figure 5.5. Solubility of wild-type and ∆CL∆CX Hsp90. 
The solubility of wild-type (A) and ∆CL∆CX (B) Hsp90 was analyzed by heating 
protein samples to the indicated temperature for five minutes and separating soluble and 
aggregated protein by Native PAGE.
138
Figure 5.5
25 40 45 50 55 60 65 70 95°C:
wild-type Hsp90
25 40 45 50 55 60 65 70 95
∆CL∆CX Hsp90
Native PAGE
Native PAGE
°C:
(A)
(B)
soluble 
protein
aggregated 
protein
soluble 
protein
139
140 
 
 
 
We next investigated how charge-rich regions of Hsp90 affect the aggregation of 
a different mis-folded protein, citrate synthase (CS). Previous studies demonstrate that 
wild-type Hsp90 is able to suppress the temperature-induced aggregation of CS (Figure 
5.3) (85). As observed for CFTR-NBD1, the CL and CX Hsp90 constructs maintained 
near wild-type anti-aggregation activity while CL CX was inefficient at suppressing 
CS aggregation (Figure 5.4B). Under the conditions of the CS aggregation experiments, 
our Hsp90 constructs do not aggregate in the absence of CS (Figure 5.4B right panel, 
Figure 5.5). Together, these results indicate that the charge-rich regions are important for 
the anti-aggregation activity of Hsp90 for two different proteins.  
 
Given the striking impact of deleting both charge-rich regions of Hsp90 on anti-
aggregation activity, we wondered if CL CX was itself mis-folded. To address this 
question we analyzed the secondary structure by circular dichroism (CD). We find that 
CL CX contains secondary structure that is indistinguishable from wild-type Hsp90 
and the individual CL and CX constructs (Figure 5.6A). We next considered the 
possibility that deleting both charge-rich regions thermodynamically destabilized Hsp90. 
Thermodynamic stability can be measured by monitoring the concentration of urea 
required to unfold the protein. We observed that similar concentrations of urea were 
required to unfold all of our constructs (Figure 5.6B). These results indicate that the 
folded domains of CL CX are well-folded and thermodynamically stable compared to 
wild-type Hsp90. It is also possible that deletion of the CL and CX disrupts the Hsp90  
Figure 5.6. Deletion of charge-rich regions does not disrupt the Hsp90 dimer or 
essential function.
(A) CD analysis indicated that all Hsp90 constructs have secondary structure content 
similar to wild-type. (B) All Hsp90 constructs unfold at similar concentrations of urea. 
The midpoint concentration (Cm) of urea required to denature Hsp90 was unchanged 
by deletion of the CL and CX (Table 5.3). (C) ∆CL∆CX Hsp90 behaves as a dimer 
during analytical ultracentrifugation. Single-species fit indicates that the molecular 
mass is 155 kDa (similar to the theoretical mass of a dimer: 151 kDa). The fit for a 
theoretical monomer is shown in grey for comparison. (D) Hsp90 constructs lacking the 
CL and CX were capable of hydrolyzing ATP similar to wild-type.
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Table 5.3. Midpoint concentrations of urea 
required to denature Hsp90 
 
 Hsp90 Cm
a
 (M) 
 
  Wild-type 4.8 
  CL 4.7 
  CX 4.6 
  CL CX 4.7 
  CR 4.5 
 
a
Midpoint concentration (Cm) is the concentration 
of urea where half the protein is unfolded 
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dimer, resulting in a non-functional monomeric construct. However, analytical 
ultracentrifugation indicates that CL CX Hsp90 is dimeric (Figure 5.6C).  
 
Because our CL constructs shorten the linker connecting the N-terminal and 
middle domains we wondered if interactions between these domains were perturbed. 
Communication between the N-terminal and middle domains is important for the inherent 
ATPase activity of Hsp90 (14). We tested ATPase activity and found that all of our 
constructs hydrolyze ATP at similar levels to wild-type Hsp90 (Figure 5.6D). This result 
indicates that our deletions do not compromise communication between the N-terminal 
and middle domains. By deleting only the acid-rich region of the CL, our constructs 
retain flexibility that was previously found to be important for proper communication 
between the N-terminal and middle domains (156, 160). 
 
Our experimental observations are consistent with a model where both wild-type 
and CL CX Hsp90 are capable of forming complexes with mis-folded proteins, but 
only wild-type Hsp90 complexes effectively suppress the aggregation of mis-folded 
proteins (Figure 5.7). It is well established that the propensity of proteins to aggregate 
increases under conditions that promote mis-folding (85-88, 139). The ability of wild-
type Hsp90 to suppress the temperature-induced aggregation of CFTR-NBD1 and CS 
indicates that it is capable of binding to these mis-folded proteins and reducing their 
propensity to aggregate. In our model, CL CX Hsp90 is also capable of binding to mis- 
Figure 5.7. Mechanistic model of charge-dependent anti-aggregation activity of 
Hsp90. 
Stress-induced mis-folding of an aggregation-prone protein leads to exposure of hydro-
phobic surfaces that cause non-specific aggregation in the absence of a chaperone. In 
our model, both wild-type and ∆CL∆CX Hsp90 bind to the mis-folded state, but only 
wild-type complexes efficiently hinder aggregation. The deficient anti-aggregation 
activity of ∆CL∆CX Hsp90 could also be caused by impaired binding to mis-folded 
protein. 
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folded conformations, but is unable to suppress the aggregation of the mis-folded 
proteins. However, our results are also consistent with a model where CL CX Hsp90 is 
defective for binding to mis-folded proteins. 
 
We developed experiments to distinguish whether CL CX is deficient for 
binding to mis-folded proteins or deficient in reducing the aggregation of bound, mis-
folded proteins. It is challenging to measure the binding of Hsp90 to mis-folded proteins 
because of the inherent technical challenge of aggregation. However, the two possible 
models make different and testable predictions regarding the anti-aggregation activity of 
mixtures of wild-type and CL CX Hsp90. If binding is the dominant defect of 
CL CX Hsp90, then mixtures of wild-type and CL CX Hsp90 should mimic the anti-
aggregation activity of wild-type Hsp90 alone. If CL CX competes with wild-type 
Hsp90 for binding to mis-folded protein, but does not protect mis-folded protein from 
aggregating, then mixtures of wild-type and CL CX Hsp90 should exhibit intermediate 
anti-aggregation activity. Because Hsp90 is dimeric, there is the potential to form wild-
type/ CL CX Hsp90 heterodimers that would complicate the interpretation of these 
mixing experiments. To avoid this complication, we utilized a super-stabilized dimer 
wild-type Hsp90 (NMCcoil) that does not heterodimerize with non-superstabilized Hsp90 
(110). We find that mixtures of NMCcoil and CL CX Hsp90 have anti-aggregation 
activity for both CFTR-NBD1 and CS that is intermediary to either Hsp90 construct 
alone (Figure 5.8A and B). These results indicate that both wild-type and CL CX  
Figure 5.8. Charge-dependent anti-aggregation activity of Hsp90. 
(A and B) To determine whether ∆CL∆CX is unable to bind mis-folded proteins or is 
deficient for suppressing the aggregation of bound protein, we monitored the ability of 
an equimolar mixed sample of ∆CL∆CX and NMCcoil Hsp90 to suppress CFTR-
NBD1 (A) or CS (B) aggregation. The intermediate anti-aggregation activity observed 
for the mixed sample indicates that both wild-type and ∆CL∆CX Hsp90 compete for 
binding to mis-folded proteins. (C) Analysis of CFTR-NBD1 aggregates formed in the 
presence and absence of Hsp90 variants. Aggregates were collected by centrifugation 
and analyzed by western blotting for Hsp90 and CFTR-NBD1. We find that most 
∆CL∆CX Hsp90 remains soluble during the CFTR-NBD1 aggregation reaction.
148
Figure 5.8
(A) (B)
50
100
0 10 20 30 40
R
el
at
iv
e 
A
gg
re
ga
tio
n
Time at 43 °C 
(minutes)
Hsp90
0
CFTR-NBD1 CS
50
100
0 5 10 15 20
R
el
at
iv
e 
A
gg
re
ga
tio
n
Time at 45 °C 
(minutes)
none
Hsp90
0
∆CL∆CX
NMCcoil
mix
none
∆CL∆CX
mix
NMCcoil
(C)
Hsp90 western
CFTR-NBD1 western
- + + + + +
+ + + + - -
- - wt ∆∆ ∆∆wt10
%
 w
t
10
%
 ∆
∆ heat
CFTR-NBD1
Hsp90
- + + + + +
+ + + + - -
- - wt ∆∆ ∆∆wt
10
0%
 N
BD
1
10
%
 N
BD
1
Fr
ac
tio
n
of
 in
pu
t
0 .2
0 .4
0
0 .2
0 .4
0
Fr
ac
tio
n
of
 in
pu
t
149
heat
CFTR-NBD1
Hsp90
150 
 
 
 
Hsp90 are capable of binding to mis-folded proteins but only wild-type Hsp90 complexes 
effectively suppress the aggregation of mis-folded proteins. 
 
Having established that CL CX Hsp90 is capable of binding to mis-folded 
proteins, we next investigated if the CL CX Hsp90 in these complexes aggregates. The 
efficiency of CL CX Hsp90 aggregation from these complexes is likely to be 
influenced by the dynamics and mechanism of the aggregation process. Because 
CL CX Hsp90 in isolation is soluble under the conditions of these experiments (Figure 
5.4), the relative amount of CL CX Hsp90 aggregation should be controlled by kinetic 
competition between aggregation and release from aggregating particles. To examine this 
issue, we monitored the content of aggregated particles formed by mis-folded CFTR-
NBD1 in the presence and absence of CL CX Hsp90 (Figure 5.8C). Under the 
conditions of the experiment, we find that CFTR-NBD1 readily aggregates on its own 
and that this aggregation is efficiently rescued by wild-type Hsp90, but not CL CX 
Hsp90 consistent with our light-scattering experiments (Figure 5.6A). Aggregates formed 
in the presence of CL CX Hsp90 show background levels of the chaperone, indicating 
that most CL CX Hsp90 remains soluble. Thus, the mechanism and dynamics of the 
aggregation process permit CL CX Hsp90 release. 
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The defective anti-aggregation activity of CL CX can be rescued by an exogenous 
acid-rich region. 
If removal of charge caused the anti-aggregation defects of CL CX Hsp90, 
adding charge back to the construct should rescue this activity. Alternatively, sequence-
specific features of the CL and CX may have caused the loss of Hsp90 anti-aggregation 
activity. To distinguish these possibilities, we appended the human Hsp90 CL to the C-
terminus of CL CX to generate a charge rescue (CR) Hsp90 construct (Figure 5.9 and 
5.10). While the charge-rich nature of the CL is evolutionarily conserved, it is one of the 
most diverse regions of Hsp90 with respect to sequence. In addition, by appending the 
human CL to the C-terminus, we have dramatically altered its physical location relative 
to the rest of the Hsp90 domains. We found that CR Hsp90 efficiently reduces CFTR-
NBD1 (Figure 5.9B) and CS (Figure 5.9C) aggregation indicating that charge modulates 
the anti-aggregation activity of Hsp90. 
 
Discussion 
Our results clearly indicate that charge is important for the anti-aggregation 
activity of Hsp90. Hsp90 has been shown to reduce the aggregation propensity of 
numerous proteins (85-88). The aggregation propensity of many proteins, including 
CFTR and CS, increases under conditions that promote mis-folding. These observations 
are consistent with a widely recognized sequential model where natively-folded proteins 
transition to mis-folded states prior to aggregation (Figure 5.7). In this model, there are  
Figure 5.9. The anti-aggregation activity of ∆CL∆CX Hsp90 was rescued by an 
exogenous acid-rich region. 
(A) The human Hsp90 CL was appended to the C-terminus of ∆CL∆CX Hsp90 (black 
square) to generate a charge-rescue construct, CR. CR Hsp90 suppressed CFTR-NBD1 
(B) and CS (C) aggregation at elevated temperature.
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Figure 5.10. Biochemical analysis of CR Hsp90.
(A) Addition of the human Hsp90 CL to the C-terminus of ∆CL∆CX Hsp90 does not 
affect secondary structure as monitored by CD. (B) The CR Hsp90 construct unfolds at 
a similar concentration of urea as wild-type Hsp90. The Cm of urea required to dena-
ture Hsp90 was unchanged by the addition of the human Hsp90 CL to the C-terminus 
of ∆CL∆CX Hsp90 (Table 5.3). (C) CR Hsp90 was capable of hydrolyzing ATP similar 
to wild-type. (D) In the absence of CFTR-NBD1, CR Hsp90 maintained wild-type 
solubility at 45 °C. (E) In the absence of CS, CR Hsp90 maintained wild-type solubility 
at 43 °C.
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three potential protein conformations (native, mis-folded, and aggregated) that may bind 
to Hsp90. 
 
Hsp90 binding to proteins in a mis-folded conformation is consistent with our 
observation that charge-rich regions of Hsp90 modulate the aggregation process. In our 
experiments, CFTR-NBD1 and CS aggregation were initiated by temperature stress, a 
condition that promotes  mis-folding (158). Mis-folded CFTR-NBD1 and CS are highly 
prone to aggregation, but this aggregation can be minimized by binding to Hsp90 (Figure 
5.4). The anti-aggregation activity of Hsp90 is impaired by deletion of the charge-rich 
regions indicating that charge plays an important role in Hsp90 anti-aggregation activity. 
Importantly, deletion of the charge-rich regions does not prevent Hsp90 from binding to 
mis-folded proteins (Figure 5.8).  
 
Although unable to prevent the aggregation of both CFTR-NBD1 and CS, 
CL CX Hsp90 alters the kinetics of the aggregation reaction for CFTR-NBD1 (Figure 
5.4A) but not for CS (Figure 5.4B). This change in the aggregation kinetics is 
concentration-dependent as it is not observed with half the concentration of CL CX 
Hsp90 (Figure 5.8A). These observations are consistent with a model where CL CX 
Hsp90 slows the aggregation of mis-folded CFTR-NBD1 but the eventual accumulation 
of aggregated protein drives the equilibrium to a fully-aggregated state.  
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In bacterial Hsp90 (HtpG), the CL and CX regions are absent (159, 161). 
However, in E. coli HtpG the net charge remains highly negative due to the amino acid 
composition of the structured regions. The estimated charge per 100 amino acids on 
HtpG is -4.2 (compared to -2.2 for CL CX). These findings suggest that net charge 
may also be valuable in bacterial Hsp90 for anti-aggregation activity though the location 
of the charge is distinct from eukaryotic Hsp90. 
 
There are two well-established physical properties of charge-rich regions that are 
likely to reduce aggregation: favorable interactions between charged atoms and aqueous 
solvent, and Coulombic repulsion between like-charged complexes. Our results indicate 
that the charge-rich regions of Hsp90 enhance the solubility of Hsp90 complexes with 
mis-folded proteins through favorable solvent interactions and Coulombic self-repulsion 
with other like-charged complexes.  
 
Net charge is a common characteristic of many chaperones and may influence 
their ability to prevent protein aggregation. We observe that net charge is a common 
characteristic of the Hsp33, Hsp70, and Hsp90 families of anti-aggregation chaperones. 
These chaperone families are also characterized by small hydrophobic patches capable of 
binding to exposed hydrophobic regions of mis-folded proteins. Our results with Hsp90 
suggest that charge may be important in the function of these chaperones. 
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CHAPTER VI 
 
Investigating the role of Hsp90 anti-aggregation activity  
in vivo 
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Abstract 
The ATP-independent anti-aggregation activity of Hsp90 observed in vitro has 
been a long-standing puzzle. In vitro, Hsp90 clearly hinders the aggregation of many 
hard-to-fold proteins without ATP. In cells, however, all of the biologically important 
functions of Hsp90 identified to date, including the maturation of kinases and nuclear 
steroid hormone receptors, clearly require ATP hydrolysis by Hsp90. Why does Hsp90 
robustly hinder the aggregation of hard-to-fold proteins without ATP in vitro, but in vivo 
uses ATP hydrolysis for all of its essential functions? By utilizing separation of function 
Hsp90 variants (that specifically lack in vitro anti-aggregation activity) we have begun to 
address this question. We find that anti-aggregation deficient Hsp90 is unable to support 
yeast growth under stressful conditions. Thus, the anti-aggregation activity of Hsp90 is 
important for its essential function in vivo. Interestingly, the ATP-independent anti-
aggregation activity of Hsp90 is not sufficient for supporting cell function. Thus, 
hindering the aggregation of most hard-to-fold proteins by Hsp90 (independent of ATP 
hydrolysis) does not appear to be important for cell function. These results suggest a 
cellular model where the Hsp40/60/70 machinery is responsible for hindering the 
aggregation of most hard-to-fold proteins while Hsp90 assists in the maturation of a 
select set of clients in an ATP-dependent fashion, potentially aided by its inherent anti-
aggregation properties.  
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Introduction 
Hsp90 is an essential molecular chaperone in eukaryotes where it is required for 
the maturation of a select group of signal transduction client proteins including numerous 
kinases and steroid hormone receptors (8, 91). Structurally, Hsp90 is a homodimeric 
chaperone consisting of an N-terminal domain that is the site of ATP binding and 
hydrolysis, a middle domain, and a C-terminal dimerization domain (10). Hsp90 mutants 
that are unable to bind or hydrolyze ATP fail to support yeast viability (11, 96) or mature 
Hsp90 client proteins in vivo (110) emphasizing the importance of ATP hydrolysis for 
Hsp90 function in vivo. 
 
In contrast to the requirement for ATP binding and hydrolysis in vivo, Hsp90 has 
been shown to robustly hinder the aggregation of numerous hard-to-fold proteins in vitro 
in the absence of ATP (85, 86, 88-90). How can essential Hsp90 function in vivo 
absolutely require ATP while in vitro Hsp90 can function as an anti-aggregation 
chaperone independent of ATP binding and hydrolysis?  
 
Interestingly, while Hsp90 has been shown to be a promiscuous anti-aggregation 
chaperone in vitro, it does not appear to be important for the proper folding of most 
cellular proteins (84). To investigate this apparent discrepancy, we tested the function of 
anti-aggregation deficient Hsp90 in yeast cells. In our previous work, we determined that 
deletion of the acidic charged linker and C-terminal extension of Hsp90 ( CL CX) 
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significantly impaired the anti-aggregation activity of Hsp90 in vitro (162). CL CX 
Hsp90 maintains wild-type ATP hydrolysis levels allowing us to investigate Hsp90 anti-
aggregation activity in vivo as well as investigate the role of ATP hydrolysis in this 
activity. 
 
Results 
Hsp90 anti-aggregation activity is required for yeast growth under stressful conditions. 
Hsp90 is an essential gene in eukaryotes (4, 115, 116). Hsp90 mutants described 
in Chapter 5 that lack in vitro anti-aggregation activity (162) were used to investigate the 
role of anti-aggregation activity in Hsp90 function in vivo. We first tested whether anti-
aggregation deficient Hsp90 mutants can support yeast viability as the sole copy of 
Hsp90. Each mutant was introduced into a yeast strain whose other source of Hsp90 was 
encoded on a URA3 plasmid that can be swapped out using 5-FOA (126). Anti-
aggregation deficient Hsp90 mutants were able to support yeast growth in the presence 
and absence of wild-type Hsp90 (Figure 6.1A) and were found to accumulate to wild-
type levels in yeast cells grown at room temperature (Figure 6.1B).  
 
Yeast cells express numerous cellular chaperones in addition to Hsp90, including 
Hsp110, Hsp70, Hsp60, and Hsp40 (163, 164). Under non-stress conditions, other 
cellular chaperones may be able to compensate for the defective anti-aggregation activity 
of Hsp90 allowing for normal growth. Anti-aggregation deficient Hsp90s may be unable  
Figure 6.1. Hsp90 anti-aggregation activity is not required for the essential 
function of Hsp90 in yeast. 
(A) All Hsp90 mutants support yeast viability when expressed as the sole copy of 
Hsp90 in yeast cells at 25 ºC. (B) Hsp90 mutants accumulate to wild-type levels in 
yeast grown at 25 ºC. 
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to support yeast growth under stressful conditions where aggregation poses a greater 
challenge to the cell. In fact, yeast strains expressing anti-aggregation deficient Hsp90 as 
the sole copy of Hsp90 were unable to grow at elevated temperature (Figure 6.2A&B).  
 
The failure to support yeast growth at elevated temperature may be due to reduced 
expression levels of anti-aggregation deficient Hsp90. To test this possibility, we 
analyzed the cellular expression levels of each Hsp90 anti-aggregation mutant in yeast 
lysates by western blotting (Figure 6.2C). The anti-aggregation deficient Hsp90 mutants 
CL and CL CX which were unable to support yeast growth under stressful conditions 
displayed reduced cellular expression levels when grown at elevated temperature for an 
extended period of time.  
 
Previous studies showed that reduced Hsp90 levels results in decreased growth at 
elevated temperatures (4). To determine whether the growth defect observed for anti-
aggregation deficient Hsp90 at elevated temperature is due to reduced expression, we 
engineered wild-type Hsp90 constructs with reduced cellular expression levels. 
Expression of wild-type Hsp90 can be reduced by changing the promoter controlling 
expression from the plasmid system (108). We first monitored the ability of two 
promoters to reduce the cellular expression of wild-type Hsp90 compared to the GPD-
expressed construct by analyzing Hsp90 levels in yeast lysates by quantitative western 
blotting (Figure 6.3A). Importantly, the GPD promoter has previously been shown to  
Figure 6.2. Hsp90 anti-aggregation activity is required for yeast growth under 
stressful conditions.
Yeast expressing anti-aggregation deficient Hsp90 as the sole copy are unable to 
support yeast growth at elevated temperature on (A) plates or (B) in liquid culture. 
Error bars represent SD, n=3. (C) Cellular expression levels of Hsp90 anti-
aggregation mutants are reduced compared to wild-type Hsp90 after 48 hours growth 
at 37 ºC.  
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Figure 6.3. Reducing cellular expression levels of Hsp90 impairs cell function.
(A) Cellular expression levels of Hsp90 were reduced by expressing Hsp90 under the 
control of 3 promoters: GPD (wild-type), TEF1, or ADH1. Expression levels in yeast 
were determined by quantitative western blotting. Intervening lanes were removed for 
presentation purposes where indicated by grey lines. (B) Yeast expressing 15 % of 
wild-type Hsp90 protein (ADH1-expressed) showed reduced viability when expressed 
as the sole copy of Hsp90 at 25 ºC.  (C) Reducing cellular expression of Hsp90 results 
in a decreased growth rate at 37 ºC. Error bars represent SD, n=3.
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express Hsp90 at endogenous levels (117). We find that expression of wild-type Hsp90 
from both the TEF1 and ADH1 promoters significantly reduces the cellular expression 
level of Hsp90. When grown under conditions that select for TEF1- or ADH1-expressed 
Hsp90 as the sole copy of Hsp90, we find that moderate reduction (TEF1) of Hsp90 
levels does not impair yeast growth but further reduction (ADH1) impairs the ability of 
Hsp90 to support yeast growth under non-stress conditions (Figure 6.3B). When grown at 
37 °C for an extended period of time TEF1-expressed Hsp90 was able to support yeast 
growth similar to wild-type but ADH1-expressed Hsp90 was significantly impaired for 
growth (Figure 6.3C) confirming that reducing Hsp90 levels leads to decreased growth at 
elevated temperatures.  
 
We next compared the cellular expression level of anti-aggregation deficient 
CL CX Hsp90 to our three wild-type Hsp90 constructs with modified expression levels 
by western blotting of yeast lysates. Under non-stress conditions, we find that CL CX 
accumulates to the level of TEF1-expressed wild-type Hsp90 (Figure 6.4A). However, 
growth under stressful conditions results in CL CX expression levels resembling 
ADH1-expressed wild-type Hsp90 (Figure 6.4B). Reducing the expression levels of wild-
type Hsp90 does not allow us to differentiate between anti-aggregation and expression 
level defects for CL CX under stressful conditions. 
 
 
Figure 6.4. How does the expression level of ∆CL∆CX Hsp90 compare to different 
expression levels of wild-type Hsp90? 
Expression levels in yeast were determined by western blotting. Intervening lanes were 
removed for presentation purposes where indicated by grey lines. (A) At 25 ºC, the 
expression level of ∆CL∆CX Hsp90 is similar to that of TEF1-expressed Hsp90. (B) 
After 9 hours at 37 ºC, the expression level of ∆CL∆CX Hsp90 more closely resembles 
that of ADH1-expressed Hsp90.
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Wild-type and anti-aggregation deficient Hsp90 proteins were expressed from 
414GPD low-copy plasmids in yeast cells. CL CX Hsp90 expression was next 
increased by utilizing a high-copy yeast expression plasmid. By expressing CL CX 
Hsp90 from the 424GPD and 424TEF1 plasmids, we observed expression levels 
comparable to that of wild-type Hsp90 under non-stress (Figure 6.5A) and stressful 
conditions (Figure 6.5B). When all wild-type and CL CX Hsp90 constructs with 
modified expression levels were grown at 37 °C for an extended period of time CL CX 
Hsp90 expressed from the 424GPD plasmid accumulated to wild-type levels (Figure 
6.5B) but was unable to support yeast growth (Figure 6.6) at 37 °C. Therefore, the 
reduced cellular expression of CL CX Hsp90 does not result in the growth defect 
observed at 37 °C and the anti-aggregation activity of Hsp90 is required for its essential 
function in vivo.  
 
ATP-independent anti-aggregation activity of Hsp90 is not sufficient for cell function.  
If the anti-aggregation activity of Hsp90 is truly ATP-independent, we should be 
able to rescue the growth defect of CL CX Hsp90 under stressful conditions with an 
otherwise non-functional Hsp90 mutant that maintains anti-aggregation activity in vitro. 
We co-expressed the ATP-binding deficient D79N Hsp90 mutant which was previously 
shown to maintain in vitro anti-aggregation activity (110) with CL CX Hsp90 and 
monitored yeast growth at elevated temperature. To prevent heterodimer formation, our 
D79N construct contained a C-terminal coiled-coil dimerization domain as described in  
Figure 6.5. ∆CL∆CX Hsp90 can be expressed at wild-type levels. 
Expression levels in yeast were determined by western blotting. (A) At 25 ºC, the 
expression level of ∆CL∆CX 424TEF1 is similar to that of wild-type Hsp90. (B) After 
8 hours at 37 ºC, expression of ∆CL∆CX Hsp90 from the 424GPD plasmid is similar to 
that of wild-type Hsp90.
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Chapter 4. D79N Hsp90 was unable to rescue the growth defect of CL CX Hsp90 
(Figure 6.7), indicating that the ATP-independent anti-aggregation activity of Hsp90 is 
not sufficient for cell function.  
 
 Our results are also consistent with a model where the growth defect observed for 
CL CX Hsp90 is a dominant defect where D79N Hsp90 is drawn into aggregates 
rendering it unable to function. To address this concern, we co-expressed wild-type 
Hsp90 (with the C-terminal coiled-coil dimerization domain) with CL CX and 
monitored growth under stressful conditions (Figure 6.7). We find that wild-type Hsp90 
is able to effectively rescue the growth defect observed for CL CX indicating that it is 
not a dominant growth defect and supporting a model where ATP-independent anti-
aggregation activity is not sufficient for Hsp90 function in cells.  
 
Discussion 
 Hsp90 efficiently suppresses the aggregation of hard-to-fold proteins in vitro in 
the absence of ATP yet all known functions of Hsp90 in vivo strictly require ATP 
hydrolysis. To investigate this discrepancy, we tested the function of Hsp90 separation of 
function mutants that lack anti-aggregation activity but maintain ATPase activity in yeast 
cells. While anti-aggregation deficient Hsp90 mutants were able to support yeast viability 
as the sole Hsp90 under non-stress conditions (Figure 6.1) they were unable to support 
yeast growth under stressful conditions (Figure 6.2). We found that after extended growth  
Figure 6.7. The ATP-independent anti-aggregation activity of Hsp90 is not 
sufficient for cell function.
The growth defect of ∆CL∆CX Hsp90 observed under stressful conditions (37 ºC) 
could not be rescued by co-expression of ATPase-deficient D79N Hsp90 but was 
rescued by co-expression of wild-type Hsp90.  Wild-type and D79N Hsp90 contained 
C-terminal coiled-coil dimerization domains to inhibit heterodimer formation. Error 
bars represent SD, n=3.
178
Figure 6.7
0.2
0.1
0
G
ro
w
th
 R
at
e 
(h
ou
rs
-1
)
wi
ld-
typ
e
∆C
L∆
CX
 + 
wi
ld-
typ
e
∆C
L∆
CX
+ D
79
N
∆C
L∆
CX
Hsp90
179
37 ºC
180 
 
 
 
at elevated temperatures, expression of anti-aggregation deficient Hsp90 was 
significantly reduced compared to wild-type Hsp90.  
 
Reducing cellular levels of Hsp90 has previously been shown to lead to growth 
defects at elevated temperature (4). When the cellular expression level of wild-type 
Hsp90 was reduced by changing the promoter on the plasmid system, significantly 
reducing Hsp90 levels resulted in impaired yeast growth at elevated temperatures (Figure 
6.3). When we compared the expression of CL CX Hsp90 to that of TEF1- and ADH1-
expressed Hsp90 under non-stress conditions, CL CX Hsp90 expression resembled 
TEF1-expressed Hsp90 (Figure 6.4A) which was able to efficiently support yeast growth. 
However, under stressful conditions, CL CX expression resembled ADH1-expressed 
Hsp90 (Figure 6.4B), which was unable to support efficient yeast growth under stressful 
conditions.  
 
To explore this issue further, we changed the expression system for CL CX 
Hsp90 to a high-copy expression plasmid in yeast. Expression of CL CX Hsp90 from 
the 424GPD and 424TEF1 high-copy expression plasmids was comparable to expression 
of wild-type Hsp90 under non-stress and stressful conditions (Figure 6.5). We found that 
after extended growth at 37 °C, CL CX Hsp90 constructs that accumulate to wild-type 
levels (Figure 6.5B) were unable to efficiently support yeast growth under stressful 
conditions (Figure 6.6). Therefore, the reduced cellular expression of CL CX Hsp90 
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does not cause the growth defect observed at 37 °C.  These results indicate that the anti-
aggregation activity of Hsp90 is required for its essential function in vivo.  
 
Our observation that CL CX Hsp90 can support yeast growth at 25 °C (Figure 
6.1) but not at 37 °C (Figures 6.2) is also consistent with an Hsp90 defect in the cell 
integrity signaling pathway. Perturbations in the cell wall caused by various cell-stresses 
including heat induces the cell integrity signaling pathway (165). Mutations of 
components of the cell integrity signaling pathway share common phenotypes including 
temperature-sensitive growth at 37 °C (165). Hsp90 is known to bind to one stress-
activated MAP kinase, Slt2, of the cell integrity signaling pathway allowing Slt2 to 
activate downstream targets (8, 166). An inability of CL CX Hsp90 to activate Slt2 at 
37 °C could also explain the observed growth defect.  
 
To differentiate between anti-aggregation and heat-induced cell integrity signaling 
pathway defects, we plan to monitor CL CX Hsp90 function in yeast cells with 
decreased levels of other cellular chaperones such as Hsp40, Hsp70, or Hsp110. Three of 
the four Hsp70 genes in S. cerevisiae can be deleted without compromising viability 
(strain: ssa1 ssa2 ssa3 or ssa1 ssa3 ssa4) (167). Either Hsp110 gene can be deleted 
(strain: sse1 or sse2) but the combined deletion of both is non-viable (168-170). The 
Hsp70 co-chaperone Hsp40 (YDJ1) could also be deleted (171, 172). By reducing the 
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abundance of other anti-aggregation chaperones, we can then monitor CL CX Hsp90 
function at 25 °C where the cell integrity signaling pathway plays a less prominent role.  
 
To further probe the role of the ATP-independent anti-aggregation activity of 
Hsp90 observed in vitro in yeast cells, we co-expressed the ATPase-deficient D79N 
Hsp90 mutant with CL CX in an effort to rescue the growth defect observed at elevated 
temperature. D79N Hsp90 was unable to rescue the growth defect of CL CX Hsp90 at 
elevated temperature (Figure 6.7) indicating that any ATP-independent function of Hsp90 
does not have a measurable impact on cell function. Importantly, the growth defect of 
CL CX is not a dominant defect as wild-type Hsp90 was able to efficiently rescue the 
growth defect of CL CX Hsp90 (Figure 6.7).  
 
In the future, we hope to further probe the role of Hsp90 anti-aggregation activity 
in vivo. The inability of an ATPase-deficient Hsp90 mutant with intact anti-aggregation 
functions to rescue the growth defect of anti-aggregation deficient Hsp90 suggests that 
hindering the aggregation of most hard-to-fold proteins by Hsp90 (independent of ATP 
hydrolysis) is not sufficient for cell function. This hypothesis is further supported by 
preliminary results from cadmium-stress experiments with anti-aggregation deficient 
Hsp90 mutants. Exposure to heavy metals provides an oxidative stress that induces the 
formation of reactive oxygen species and damaged proteins (173). Growth of yeast 
expressing anti-aggregation deficient Hsp90 mutants was not affected by the addition of 
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cadmium chloride at 25 or 37 °C (data not shown) confirming that Hsp90 is not required 
for proper maintenance of most cellular proteins. These results suggests a possible 
cellular model where the Hsp40/60/70 machinery is responsible for hindering the 
aggregation of most hard-to-fold proteins while Hsp90 primarily assists in the maturation 
of a select set of clients in an ATP-dependent fashion, potentially aided by its inherent 
anti-aggregation properties. 
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CHAPTER VII 
 
Discussion and Future Directions 
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In this thesis, I provide a thorough evaluation of how dimerization of Hsp90 
contributes to its function in cells and the role of ATP binding and hydrolysis in client 
protein activation by Hsp90. I also show how the net charge of Hsp90 modulates its anti-
aggregation activity in vitro and provide some initial insights into the role of Hsp90 anti-
aggregation activity in vivo. Previous studies suggested that the ATPase activity of Hsp90 
is required for its essential function in vivo but the details of this activity remained to be 
elucidated. I provide evidence that Hsp90 ATPase activity requires a functional Hsp90 
dimer and that this ATPase activity is required for client protein activation in cells by 
Hsp90. I also discovered that Hsp90 anti-aggregation activity is regulated by negative 
charge and began investigating the role of Hsp90 anti-aggregation activity in cells. 
 
 Previous studies showed that Hsp90 monomers have significantly reduced 
ATPase activity (93). However, given the large network of Hsp90 co-chaperone and 
client protein interactions (8), it is essential that the role of Hsp90 monomers be studied 
in cells. We created a monomeric Hsp90 construct, NMCC, and showed that dimerization 
is required for Hsp90 function in yeast cells (Chapter 3). Hsp90 monomers have 
significantly reduced ATPase activity in vitro, are unable to support yeast viability, and 
are unable to activate the Hsp90 client proteins v-src and GR in vivo. NMCC Hsp90 
provides a useful tool for studying the potential role of monomers in the Hsp90 
conformational cycle and to study possible interactions of Hsp90 monomers with co-
chaperones and substrate proteins.  
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 To further understand the precise mechanism of ATP-binding and hyrolysis by 
Hsp90 and its implications for Hsp90 function, we explored the role of Hsp90 ATPase 
activity in client protein maturation in yeast cells. Hsp90 ATPase mutants E33A and 
D79N are unable to support yeast viability (11, 96) but the role of Hsp90 ATPase activity 
in client protein maturation was previously unknown. Our work in Chapter 4 showed that 
ATP binding and hydrolysis by Hsp90 are necessary for proper maturation of the Hsp90 
clients v-src and GR in vivo.  
 
 Interestingly, the R380A ATP-hydrolysis mutant which is non-viable (14) was 
unable to mature v-src but was able to activate GR to a significant level (Figure 7.1). To 
explore this further, I would next like to test whether this activity is specific for activation 
of GR or whether R380A Hsp90 is able to activate other hormone receptors such as the 
androgen or progesterone receptors. In order to explore this mechanism in greater depth, I 
can also use the previously described system for reconstituting hormone receptor 
activation in vitro (62) to determine if the chaperone system is altered for activation of 
hormone receptors by R380A Hsp90 compared to wild-type. 
 
 Numerous Hsp90 client proteins have been identified and studied extensively in 
vivo. Hsp90 has also been shown to suppress the in vitro aggregation of a number of 
hard-to-fold proteins. However, the mechanism of Hsp90 anti-aggregation activity is not  
Figure 7.1. R380A Hsp90 can activate GR but not v-src in yeast.
(A) As was observed for the Hsp90 ATPase mutants in Chapter 4, the R380A mutation 
to Hsp90 which inhibits ATP hydrolysis leads to reduced v-src accumulation and 
background levels of tyrosine kinase activity in yeast. (B) Unlike the inability of E33A 
and D79N Hsp90 to activate GR observed in Chapter 4, R380A Hsp90 showed reporter 
activity levels significantly greater than background using a single-tailed student T-test. 
Error bars represent SEM. (C) Expression level of GR analyzed by Western blots of 
yeast lysates. (D) Dose response to varying DOCS concentration for R380A and wild-
type Hsp90.
187
Figure 7.1
(B)(A)
0
0.5
1
w
ild
 t
yp
e 
(N
M
C
)
N
M
C
co
il
N
M
C
co
il 
D
79
N
N
M
C
co
il 
E3
3A
N
M
C
co
il 
R3
80
A
n
o
n
e
10 µM DOCS
p < 0.01
0
0.5
1
0 10 20 30
[DOCS] (µM)
R
el
at
iv
e 
R
ep
o
rt
er
 L
ev
el
s
R380A (NMCcoil)
wild-type (NMC)
+ ++++v-src induced: - - - - -
n
o
n
e
w
t
w
t
E3
3A
D
79
N
50
37
75
150
MW (kD)
phospho
tyrosine
Western
v-src
Western
NMCcoil
Rescue
Hsp90:
Coomassie
(load control)
+-
R3
80
A
(C) (D)
GR Western
Coomassie
(load control)
n
o
n
e
w
t
E3
3A
D
79
N
NMCcoil variant
R3
80
A
188
R
el
at
iv
e 
R
ep
o
rt
er
 L
ev
el
s
189 
 
 
 
well understood. Unlike all other known functions of Hsp90, the ability of Hsp90 to 
suppress the aggregation of these hard-to-fold proteins often occurs in the absence of 
ATP. But what is promoting the solubility of complexes between Hsp90 and mis-folded 
proteins was largely unknown.  
 
In Chapter 5, we showed that the negative charge of Hsp90 modulates its anti-
aggregation activity. Specifically, the highly charged CL and CX of Hsp90 provide the 
negative charge to Hsp90 required to modulate its anti-aggregation activity. The addition 
of an exogenous charge-rich region to an Hsp90 construct lacking both the CL and CX 
rescued the observed anti-aggregation defect confirming the importance of charge for 
Hsp90 anti-aggregation activity. 
 
 One question that arises from these results is how the charge of hard-to-fold 
proteins affects their interaction with Hsp90. Full-length CFTR protein is positively 
charged (Table 7.1). Several highly charged motifs in CFTR have been identified 
including negatively charged motifs in the N- and C-terminal tails and three positively 
charged motifs in the R-domain (174). The NBD1 region of CFTR used in the 
aggregation experiments is negatively charged. In contrast, CS is positively charged 
(Table 7.1) suggesting that the interaction of Hsp90 with mis-folded proteins is not 
dependent on the charge of the mis-folded protein. To confirm this observation, charge- 
reversal mutations could be made to CFTR-NBD1 and CS and the ability of Hsp90 to 
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Table 7.1. Protein charge analysis of select Hsp90 anti-aggregation substrates 
Human Protein  GenBank accession  net number of  charge per 100 
  number   charge
a
 amino acids amino acids 
CFTR  NP 000483 22.5 1480 1.5  
CS   AF053631 4.8 466 1.0 
a
Predicted net charge at pH 7, determined with the program SEDNTERP. 
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 prevent the aggregation of these mis-folded proteins tested.  
 
 Our charge analysis of other cytoplasmic proteins (Table 5.1) suggests a potential 
shared mechanism of anti-aggregation activity among chaperones that utilize 
hydrophobic patches. Analysis of the charge properties of the yeast small heat shock 
proteins Hsp26 and Hsp42 as well as A-crystallin, the closest mammalian homolog to 
Hsp26 (175), indicates they are also highly negatively charged (Table 7.2). The Hsp110 
chaperone is negatively charged and its charge is evolutionarily conserved (Table 7.3). 
To investigate this potential shared mechanism of anti-aggregation activity further, I 
could mutate regions of surface exposed charge on these other negatively charged 
chaperones and determine if net charge is important for their anti-aggregation activity.  
 
 In addition to cellular chaperones, other cellular molecules are also highly 
charged which may play a role in their solubility and function. For example, both DNA 
and RNA are highly negatively charged. In the case of RNA, this negative charge has 
been shown to play a role in the solubility of partner proteins (120). To explore the anti-
aggregation characteristics of these highly charged cellular molecules, I could test the 
ability of DNA and RNA to suppress the in vitro aggregation of hard-to-fold proteins 
such as CFTR-NBD1 and CS. Studying the role of charge in general solubility in the cell 
could increase our understanding of why charge is so often evolutionarily conserved and 
how cells control general protein aggregation problems. Given the interest in developing  
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Table 7.2. Protein charge analysis of small heat shock proteins 
Chaperone  GenBank accession  net number of  charge per 100 
  number   charge
a
 amino acids amino acids 
Hsp26 (S. cerevisiae) CAA85016  -4.8 214 -2.3 
A-crystallin (H. sapiens) AAA97523  -4.3 173 -2.5 
Hsp42 (S. cerevisiae) NP 010456 -21.5 375 -5.7 
a
Predicted net charge at pH 7, determined with the program SEDNTERP. 
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Table 7.3. Protein charge analysis of Hsp110 chaperone 
Species  GenBank accession  net number of  charge per 100 
  number   charge
a
 amino acids amino acids 
Homo sapiens Q92598 -24.0 858 -2.8  
Mus musculus NP 038587 -22.6 858 -2.6 
Saccharomyces cerevisiae 3D2F_A -16.4 658 -2.5 
a
Predicted net charge at pH 7, determined with the program SEDNTERP. 
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 treatments for aggregation-based diseases, understanding how cells regulate protein 
aggregation has important therapeutic implications.  
 
All known Hsp90 functions in cells identified to date are ATP-dependent yet 
Hsp90 efficiently suppresses protein aggregation in vitro in the absence of ATP. 
Interestingly, in Chapter 4 we found that the ATPase-deficient E33A and D79N Hsp90 
mutants were able to efficiently suppress the aggregation of CFTR-NBD1 (Figure 4.5) 
further suggesting that Hsp90 anti-aggregation activity is an ATP-independent process. 
This left us wondering whether there is an unidentified Hsp90 anti-aggregation function 
in cells that does not require ATP or if the in vitro ATP-independent activity of Hsp90 is 
an artifact. This question was examined more closely in Chapter 6.  
 
 Using the Hsp90 charge mutants described in Chapter 5 that lack anti-aggregation 
activity but maintain ATPase activity (Figures 5.4 and 5.6), we tested the role of Hsp90 
anti-aggregation activity in cells. Our results suggest that the anti-aggregation activity of 
Hsp90 is required for cell growth under stressful conditions (Figure 6.2). We also found 
that any ATP-independent function of Hsp90 that exists is not sufficient for cell function 
(Figure 6.7). This leads us to a preliminary model where the anti-aggregation activity of 
Hsp90 is important for growth under stressful conditions where it contributes to an ATP-
dependent function of Hsp90. 
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Hsp90 has been implicated in the maturation of many kinases and hormone 
receptors but there is little evidence that the anti-aggregation activity of Hsp90 is required 
for the proper activation of these clients. However, my results in Chapter 6 suggest that 
Hsp90 anti-aggregation activity is important for cell function. In the future, yeast strains 
expressing anti-aggregation deficient CL CX Hsp90 can be used to identify 
endogenous anti-aggregation substrates of Hsp90. The protein composition of soluble and 
insoluble fractions of yeast lysates prepared from cells collected during growth under 
various stress conditions such as elevated temperature, heavy metal exposure, or reduced 
cellular chaperone levels can be analyzed by mass spectrometry analysis. These 
experiments would provide further evidence for the role of Hsp90 anti-aggregation 
activity in vivo.  
 
Future experiments will be designed to establish a clearer picture of how the 
ATPase activity of Hsp90 is coordinated within the dimeric structure of Hsp90 and how 
this regulates the function of Hsp90 in cells. Using our new understanding of Hsp90 anti-
aggregation activity, the role of Hsp90 anti-aggregation activity in vivo can be further 
investigated and used to identify novel Hsp90 anti-aggregation substrates. This 
information can then be used to elucidate the mechanism(s) of client protein activation by 
Hsp90 and determine how its anti-aggregation activity contributes to client protein 
activation. 
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Conclusion 
 In this thesis, I have extensively studied the function of Hsp90 in vitro and in 
vivo. I have shown that Hsp90 monomers are non-functional and that ATPase activity is 
required for Hsp90 function in vivo. I have also shown that negative charge modulates 
Hsp90 anti-aggregation activity in vitro and that this anti-aggregation activity is required 
for Hsp90 function in yeast under stressful conditions. While I have learned a lot about 
the requirement for ATPase activity for Hsp90 function in vivo and about Hsp90 anti-
aggregation activity, there are many questions left to be answered to truly understand 
Hsp90 function. The molecular mechanism by which Hsp90 catalyzes the maturation of 
any client is an open and active area of research. Current structural models indicate that 
Hsp90 undergoes dramatic rearrangements in response to ATP binding and hydrolysis 
(10, 19, 20). However, how these structural rearrangements lead to client maturation is 
not clear. In the coming years, research will help to reveal the molecular mechanism by 
which Hsp90 binds to client proteins and along with co-chaperones and ATP catalyzes 
the maturation of these clients to active states.  
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APPENDIX I 
 
Chaperoning of yeast kinases by Hsp90 
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Introduction 
 Hsp90 is important for the activation and cellular stability of many kinases 
including then non-receptor tyrosine kinases c-src and v-src, serine/threonine kinases, 
such as Raf and Akt, and tyrosine kinases such as ErbB-1 and ErbB-2 (42, 71, 93, 176-
181). Recent large-scale screening efforts have identified many novel Hsp90 client 
kinases that warrant further investigation (8, 166). 
 
The chaperoning of protein kinases by Hsp90 occurs almost exclusively in 
cooperation with Cdc37, a co-chaperone known to protect nascent kinase chains from 
rapid degradation during or immediately following translation and promote kinase 
maturation to the folded state (75). A recent study found that more than 50 % of the S. 
cerevisiae kinome was affected by the loss of active Cdc37 (75) demonstrating the 
importance of the Hsp90:Cdc37 complex in kinase stability and activation.  
 
The majority of Hsp90-dependent kinases have been identified primarily by 
changes in cellular accumulation upon Hsp90 inactivation. In this work, we set out to 
distinguish whether Hsp90 client kinases require Hsp90 for stability, for activation, or for 
both. 
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Results 
Hsp90 is important for kinase accumulation in yeast cells. 
In order to compare changes in cellular kinase accumulation to changes in kinase 
activity upon Hsp90 inactivation we studied ten S. cerevisiae kinases (Table A.1).  Where 
known, the dependence of the kinases on Cdc37 for stability is noted (75). GST-tagged 
kinases were expressed in a yeast strain expressing a temperature-sensitive Hsp90 mutant 
as the sole copy of Hsp90. Kinases were expressed at the non-permissive temperature in 
the presence and absence of a rescue copy of Hsp90 and kinase accumulation measured 
by western blotting (Figure A.1A). Eight out of ten of the kinases were found to have 
more than a 50 % reduction in cellular accumulation upon Hsp90 inactivation indicating 
that their steady-state levels in yeast cells are dependent on Hsp90.  
 
For the hormone receptor GR, Hsp90 is required for opening the ligand-binding 
cleft allowing access of to the steroid and subsequent GR activation (182). Some kinases 
have distinct kinase and regulatory domains that bind to each other in the inactive form 
(183). We propose a model where Hsp90 is required for the displacement of regulatory 
domains from the kinase domain of client kinases leading to activation similar to the 
opening of the hormone receptor structure to allow steroid binding. 
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Table A.1. Yeast kinases used in this study. 
 
 Kinase Cdc37 Dependent?(75) Substrate 
 
 Tpk2 yes YFR017C 
 Cmk1 yes YDL006W (Ptc1) 
 Rim11 yes YPL077C 
 Ste11 yes YOL016C (Cmk2) 
 Cmk2 no YER064C 
 Cdc5 no YDR360W 
 Sky1 no YGL105W (Arc1) 
 Ste20 no YBR071W 
 Kns1 unknown MBP 
 Kin28 unknown  
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Figure A.1. Hsp90 influences the cellular accumulation of numerous yeast kinases.
Cellular  accumulation of (A) full-length kinases and (B) isolated kinase domain 
constructs measured in the presence (+) or absence (-) of active Hsp90. Error bars 
represent SD, n=3. 
Figure A.1
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If Hsp90 is required for the displacement of regulatory domains from the kinase 
domain of client kinases, isolated kinase domain constructs would not require Hsp90 for 
activation. We generated isolated kinase domain constructs (Table A.2) for nine out of 
the ten kinases tested (Kin28 does not have a regulatory domain) and monitored the 
accumulation of the kinase domains in the absence of active Hsp90 (Figure A.1B). 
Interestingly, the isolated kinase domains for Sky1 and Cdc5 were far less dependent on 
Hsp90 for cellular accumulation than their full-length counterparts.  
 
Role of Hsp90 in kinase activation. 
In order to monitor changes in kinase activity upon Hsp90 inactivation, we set out 
to identify peptide substrates for each kinase. Ptacek et al. identified in vitro substrates of 
most yeast protein kinases using proteome chip technology (184). Using substrates 
identified for each of our kinases (Table A.1), we designed eleven amino acid peptides 
surrounding every serine or threonine in the substrate protein. Peptides were synthesized 
on amino-PEG cellulose membranes (MIT Biopolymers Laboratory). To identify peptide 
substrates, cellulose membranes were incubated with purified yeast proteins and 32P-
ATP. As a control for non-specific phosphorylation by contaminating yeast kinases in the 
purified samples, a non-kinase GST-tagged control protein was purified from yeast and 
incubated with the cellulose membranes and 32P-ATP first. Any peptide phosphorylated 
by the non-kinase control sample was considered background. The cellulose membranes 
were then incubated with the corresponding kinase and 32P-ATP (Figures A.2 and A.3).  
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Table A.2. Yeast kinase domain constructs 
 
 Kinase Kinase Domain
a
 
 Tpk2  
  1 61  380  
 Cmk1  
  1 16     308  446 
 Rim11  
  1 17    329 370 
 Ste11  
  1    398    717 
 Cmk2  
  1 35     328  447 
 Cdc5  
  1  56     362    705 
 Sky1  
  1  138    304    537 742 
 Ste20  
  1      594    910 939 
 Kns1  
  1    294   737   
 Kin28
b
  
   13   303 370 
a
Shaded region is the predicted kinase domain based on BLAST search.  
b
Kin28 was primarily predicted to be a kinase domain. No isolated kinase domain 
construct was made. 
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Figure A.2. Identification of peptide substrates for yeast kinases.
Example of peptide substrate identification for the yeast kinase Tpk2. (A) 11-mer 
peptides were synthesized on cellulose membranes. Peptides were first incubated with a 
non-kinase control protein purified from yeast and 32P-ATP to determine background 
from purification procedure. Peptides were then de-phosphorylated and incubated with 
purified kinase and 32P-ATP. (B) Signal from spots was quantified using Multi Gauge 
and the signal was normalized for background phosphorylation. Peptide selected for 
further investigation is indicated (*).
Figure A.2
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Figure A.3. Phosphorylation of select peptide substrates for yeast kinases.
Potential peptide substrates for four additional kinases were phosphorylated more than 
three times greater than background in the presence of kinase. Graphs illustrate the ratio 
of specific:non-specific activity for (A) Rim11, (B) Ste11, (C) Cmk2, and (D) Sky1. 
The sequences for the selected peptides (*) are shown in Table A.3.
Figure A.3
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Peptide substrates were identified for four kinases: Tpk2, Sky1, Cmk2, Ste11 (Table 
A.3). 
 
A recent study used a rapid peptide screening approach to determine consensus 
phosphorylation site motifs for 61 out of 122 kinases in S. cerevisiae (185). Using these 
results, we generated ideal peptide substrates for Tpk2 and Cmk2 to complement our 
experimentally-derived peptides. We also tested a previously reported myelin basic 
protein (MBP) peptide for the kinase Kns1 (186) and a commercially available peptide 
sequence for Tpk2 (Promega). All peptides were synthesized with an N-terminal 
fluorophore, 5CF, followed by a 7 amino acid peptide solubility tag (109) to enhance 
peptide solubility.  
 
Fluorescently-labeled peptides were incubated with purified kinases and 32P-ATP. 
Phosphorylation was measured by gel shift on Native-PAGE (Figure A.4). Unfortunately, 
we were not able to detect significant phosphorylation of any of our peptide substrates. 
One possibility is that our kinases require a co-factor for full activity that is not present. 
This is unlikely given that the purification was completed in the same manner for the 
initial peptide substrate identification. To test this possibility, we monitored peptide 
phosphorylation following incubation with yeast lysates over-expressing the kinase of 
interest. We are able to see a gel shift for 3 of the peptides when incubated with the 
lysates, however, the shift is larger than expected for a single phosphorylation event and  
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Table A.3. Potential peptide substrates for select S. cerevisiae kinases. 
 
 Kinase  Peptide   Peptide Peptide 
  Name  Sequence
a
 Source   
 Tpk2 Tpk2-A 5CF-NKKGRHGMIRRRSTNYMD this work 
 Tpk2 Tpk2-B 5CF-NKKGRHGLRRASLG Promega
b
 
 Tpk2 Tpk2-C 5CF-NKKGRHGRRRRPSQDDD (185)      
 Cmk2 Cmk2-A 5CF-NKKGRHGKKLLDSKKKIA this work 
 Cmk2 Cmk2-B 5CF-NKKGRHGLRRRRTFYYY (185) 
 Sky1 Sky1-A 5CF-NKKGRHGADEDVSKKAKK this work 
 Kns1 Kns1-A 5CF-NKKGRHGSGSPMARR (186) 
a
Peptides have an N-terminal 7 amino acid solubility tag: NKKGRHG (109). 
bKemptide is a synthetic peptide substrate for cAMP-dependent protein kinase known 
to be phosphorylated by Tpk2 (75). 
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Figure A.4. Example gel shift experiments to monitor peptide phosphorylation.
Peptides were incubated alone, in the presence of yeast lysates or the in the presence of 
protein (kinase or control) purified from yeast lysates for 30-60 minutes at 30 °C then 
separated on 6 % Hepes/Imidazole Native gels. Peptides (A) Tpk2-B, (B) Ste11-A, and 
(C) Cmk2-A show reduced mobility in yeast lysates independent of kinase over-
expression. Reduced mobility may indicate phosphorylation or degradation. Peptides 
(D) Sky1-A and (E) Kns1-A do not show any shift in the presence of kinase. 
Figure A.4
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not specific for over-expression of the kinase of interest (Figure A.4A,B&C). For Sky1 
and Kns1 peptide substrates, no shift was observed when incubated with purified kinase 
or yeast lysates (Figure A.4D&E).  
 
Discussion and Future Directions 
Comparison of kinase steady-state levels identified potential Hsp90 client yeast 
kinases (Figure A.1A). Interestingly, all kinases tested accumulated at reduced levels in 
the absence of active Hsp90 suggesting a general regulatory role for Hsp90 in kinase 
stability. To explore this further, we plan to monitor changes in cellular accumulation of a 
known Hsp90 client kinase (v-src) and a non-Hsp90 client protein (SspB) to determine if 
this defect is specific to kinase clients or is the result of a general protein stability defect 
upon Hsp90 inactivation. However, the cellular levels of eight of the ten kinases tested 
were more than 50 % lower in the absence of active Hsp90 identifying them as potential 
Hsp90 client kinases.  
 
Although numerous Hsp90 client kinases have been identified previously, there is 
little information available about the mechanism of kinase activation by Hsp90. Recent 
evidence suggests that kinases bind to Cdc37 and this complex then binds to Hsp90 (21, 
24). But what happens once the Cdc37:kinase complex is bound to Hsp90? We propose a 
model where Hsp90 promotes the opening of the kinase structure to separate the 
regulatory domain from the kinase domain allowing activation of the kinase. To test this 
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model, we generated isolated kinase domain constructs and monitored changes in cellular 
accumulation upon Hsp90 inactivation (Figure A.1B). When compared to cellular levels 
of full-length kinases, we found that the accumulation of two isolated kinase domain 
constructs was less dependent on Hsp90 than the full-length kinases. These two kinase 
domain constructs, Sky1 and Cdc5, accumulate to a similar level as their full-length 
counterparts expressed in the presence of active Hsp90 even when Hsp90 is inactivated. 
This suggests these kinases may require Hsp90 to separate the regulatory domain from 
the kinase domain promoting activation and enhanced cellular stability. 
 
To really understand the mechanism of kinase activation by Hsp90, we need to 
test kinase activity in the absence of active Hsp90 in addition to monitoring changes in 
cellular accumulation. Our initial attempts to identify peptide substrates for our panel of 
yeast kinases yielded peptide substrates for four kinases (Figure A.2). However, initial 
efforts to develop activity assays using these peptide substrates have been unsuccessful 
(Figure A.4).  One possible explanation is that the substantial fraction of peptide required 
to observe a gel shift is not being phosphorylated whereas the experiments using 32P-ATP 
are more sensitive to smaller populations of phosphorylated peptide.  
 
A possible explanation for the observed non-specific potential phosphorylation of 
the peptides is that they are being degraded during incubation in yeast lysates. Yeast 
lysates were prepared in the presence of the serine protease inhibitor PMSF but there are 
215 
 
 
 
many other proteases and peptidases present in yeast lysates. To test this, we obtained 
two additional peptides with C-terminal amide protecting groups. Combined with 
additional protease inhibitors, we hope that the degradation of the peptides will be 
reduced and the activity of the kinases can be assayed in yeast lysates.  
 
In the event that kinase activity assays cannot be worked out with our peptide 
substrates, there are other potential activity assays that could be developed. One option 
would be to use a traditional non-specific kinase substrate such as MBP. Another option 
would be to purify the full-length substrate proteins and monitor phosphorylation when 
incubated with kinase and 32P-ATP.  
 
With an activity assay for our kinases, we hope to be able to compare changes in 
cellular accumulation to changes in activity upon Hsp90 inactivation. By comparing full-
length and isolated kinase domain contructs, we can hopefully gain more information 
about the mechanism of kinase activation by Hsp90. 
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